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METHODS FOR IDENTIFYING LIGANDS
THAT TARGET NUCLEIC ACID
MOLECULES AND NUCLEIC ACID
STRUCTURAL MOTIFS
The present application claims the benefit of U.S. Provi-
sional Patent Application Ser. No. 60/861,630, filed Nov. 29,
2006, which provisional patent application is hereby incor-
porated by reference.
STATEMENT AS TO FEDERALLY SPONSORED
RESEARCH
This invention was made with Government support under
contract number NNA05CS96G awarded by NASA. The
Government has certain rights in the invention.
FIELD OF THE INVENTION
The present invention relates to methods and materials for
systematically identifying RNA-ligand interactions, and,
more particularly, to methods and materials that can be used
to identify small molecules that target particular RNA
motifs.
The present application cites a number of references,
some or all of which are cited by number in square brackets.
The references thus cited are listed in a section entitled
"References" immediately before the claims. Each reference
cited in this application, whether by number or otherwise, is
hereby incorporated in its entirety, by reference.
BACKGROUND OF THE INVENTION
RNA forms complex tertiary structures that impart diverse
functions [1,2]. For example, RNA catalyzes reactions [3],
regulates gene expression [4, 5], encodes protein, and plays
other essential roles in biology. Therefore, RNA is an
interesting and important target for developing drugs or
probes of function [6,7]. It is a vastly underutilized target,
however, mainly because of the limited information avail-
able on RNA ligand interactions that could facilitate rational
design.
One advantage of using RNA as a drug target is that
secondary structure information, which includes the motifs
that comprise an RNA, can be easily obtained from sequence
by free energy minimization [8,9] or phylogenic comparison
[10]. RNA tertiary structures are composites of the second-
ary structural motifs and the long-range contacts that form
between them. Furthermore, RNA motifs can have similar
properties both as isolated systems and as parts of larger
RNAs. For example, aminoglycoside antibiotics affect the
structure of the bacterial rRNA A-site similarly when they
bind the entire ribosome or an oligonucleotide mimic of the
bacterial rRNA A-site [11-16]. Studies on the binding of
aminoglycosides and streptamine dimers to RNA hairpins
[17-20] have facilitated the development of compounds to
combat multidrug resistance by causing plasmid incompat-
ibility [19, 20]. These results show that the identification of
RNA motifs that bind small molecules can be useful for
targeting the larger RNAs that contain them.
However, since RNA can adopt diverse structures, inter-
nal and hairpin loops for example, an understanding how to
target RNA with small molecules and other ligands has not
yet been achieved. Current methods to study and identify
RNA ligand interactions include systematic evolution of
ligands by exponential enrichment ("SELEX") [21, 22],
structure-activity relation-ships ("SAR") by mass spectrom-
2
etry ("MS") [23-26] and NMR [27], and chemical microar-
rays [28-30]. These methods probe RNA space (SELEX) or
chemical space (SAR by MS and NMR and chemical
microarrays) separately. However, these methods do not
5 permit a systematic study of RNA-ligand interactions.
For all of the above reasons, a need exists for methods that
can be used to systematically identify RNA-ligand interac-
tions, and the present invention is directed, in part, to
addressing this need.
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SUMMARY OF THE INVENTION
The present invention relates to a method for identifying
a nucleic acid motif which interacts with a ligand. The
15 method includes providing a plurality of ligands immobi-
lized on a support, wherein each particular ligand is immo-
bilized at a discrete location on the support; contacting the
plurality of immobilized ligands with a nucleic acid motif
library under conditions effective for one or more members
20 of the nucleic acid motif library to bind with the immobi-
lized ligands; and identifying members of the nucleic acid
motif library that are bound to a particular immobilized
ligand.
The present invention also relates to a method for select-
25 ing, from a plurality of candidate ligands, one or more
ligands that have increased likelihood of binding to a nucleic
acid molecule comprising a particular nucleic acid motif.
The method includes providing a database which correlates
various ligands' abilities to bind to the particular nucleic
30 acid motif and various other nucleic acid motifs; comparing
the candidate ligands' ability to bind to the particular nucleic
acid motif; and choosing one or more ligands based on their
ability to bind to the particular nucleic acid motif.
The present invention also relates to a method for select-
35 ing, from a plurality of candidate ligands, one or more
ligands that have increased likelihood of binding to a first
nucleic acid molecule comprising a first particular nucleic
acid motif and that have decreased likelihood of binding to
a second nucleic acid molecule comprising a second par-
40 ticular nucleic acid motif. The method includes providing a
database which correlates various ligands' abilities to bind
to the first particular nucleic acid motif, to the second
particular nucleic acid motif, and to various other nucleic
acid motifs; comparing the candidate ligands' ability to bind
45 to the first particular nucleic acid motif and to the second
particular nucleic acid motif; and choosing one or more
ligands based on their ability to bind to the first particular
nucleic acid motif and their inability to the second particular
nucleic acid motif.
50 The present invention also relates to a method for iden-
tifying a nucleic acid which interacts with a ligand. The
method includes providing a plurality of ligands immobi-
lized on a support, wherein each particular ligand is immo-
bilized at a discrete location on the support; contacting the
55 plurality of immobilized ligands with a nucleic acid library
under conditions effective for one or more members of the
nucleic acid library to bind with the immobilized ligands;
and identifying members of the nucleic acid library that are
bound to a particular immobilized ligand.
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BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1A is a drawing showing the structures of small
molecule ligands that can be used in the methods of the
65 present invention. 1 is kanamycin A and 2 is 6'-N-5-hexyno-
ate kanamycin A that was used in chemical microarray-
based assays to study binding to selected RNA internal
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loops. FIG. 1B is a reaction scheme showing the synthesis
of 6'-N-5-hexynoate kanamycin A (2).
FIG. 2 is a drawing showing the sequence and structure of
oligonucleotides that can be used in the methods of the
present invention. RI (SEQ ID NO:3) is an RNA motif
library displaying a random 30 internal loop in which N
refers to a random mixture of A, C, G, and U. R2, R3, Dl,
and D2 are chase oligonucleotides. Structure R2 is a duplex
(SEQ ID NO:4 and SEQ ID NO: 5) that is related to the stems
of RI; R3 (SEQ ID NO:6) is a short hairpin having the
hairpin sequence and closing base pair of RI; Dl (SEQ ID
NO:7 and SEQ ID NO:8) and D2 (SEQ ID NO:9 and SEQ
ID NO: 10) are DNA chase oligonucleotides. The RNA R4
(SEQ ID NO: 11) is the cassette into which the library was
inserted as shown in RI.
FIG. 3 is a drawing showing the secondary structure of the
RNA internal loops and the closing base pairs that were
selected to bind immobilized kanamycin A using a method
according to the present invention. Secondary structures
were modeled using free energy minimization using the
program RNAStructure. The internal loop library (R1 (SEQ
ID NO:3)) is shown at the upper left, and the boxed
nucleotides are shown on the right for the selected internal
loops ("IL") that bind to kanamycin A (i.e., IL 1 (SEQ ID
NO: 12), IL 2 (SEQ ID NO: 13), IL 3 (SEQ ID NO: 14), IL 4
(SEQ ID NO: 15), IL 5 (SEQ ID NO: 16), IL 6 (SEQ ID
NO: 17), IL 7 (SEQ ID NO: 18), IL 8 (SEQ ID NO: 19), IL 9
(SEQ ID NO:20), IL 10 (SEQ ID NO:21), IL 11 (SEQ ID
NO:22), IL 12 (SEQ ID NO:23), IL 13 (SEQ ID NO:24), IL
14 (SEQ ID NO:25), IL 15 (SEQ ID NO:26), IL 16 (SEQ ID
NO:27), IL 17 (SEQ ID NO:28), IL 18 (SEQ ID NO:29).
Values under each loop represent the ICso (nM). Values
under internal loop library RI are the ICso (nM) values for
RI (random), for chase oligonucleotides R2, R3, Dl, and
D2, for cassette R4, and for bulk tRNA from yeast.
FIGS. 4A and 4B show the optimization of click chem-
istry conditions for immobilization of fluorescein labeled-6'
hexynoate neamine onto azide displaying surfaces. FIG. 4A
shows a reaction of FITC-labeled 6'-N-5-hexynoate neamine
with azide displaying agarose slides under click chemistry
conditions. The reaction was not analyzed for its isomeric
content, and, therefore, a single FITC isomer is drawn for
simplicity. FIG. 4B is an image of an array after reaction of
FITC-labeled 6'-N-5-hexynoate neamine with azide display-
ing agarose slides with a variety of conditions. The concen-
trations of each component in these reactions are 5 mM
sodium ascorbate, 1 MM CuSO4, 100 µM TBTA, and 80 µM
of 6'-N-5-hexynoate neamine-Fl.
FIG. 5A is a photograph of a silicon gasket affixed to a
microarray with half of the wells filled with a solution of
dye. FIG. 5B is an autoradiogram of an array-based com-
petitive binding assay completed with 5 different oligonucle-
otides. FIG. 5C is a graph showing the fit of the data for IL
9, the control oligonucleotides (R2, R3, and D1+D2), and
the cassette (R4).
FIGS. 6A and 6B are bar graphs showing nuclease map-
ping results in the presence and absence of 6' hexynoate
kanamycin A. Bold nucleotides are protected from modifi-
cation in the presence of compound. FIG. 6A shows that
binding with IL 7 (SEQ ID NO: 18) occurs only in the
randomized regions from the original library. FIG. 6B shows
that no nucleotides are protected from modification in the
hairpin cassette (R4) (SEQ ID NO:11). Plots are ratio of
counts for each nucleotide as a function of 6' hexynoate
kanamycin A. The concentrations of compound are 0, 0. 1, 1,
10, and 100 µM.
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FIG. 7 is a drawing showing the structures of various
aminoglycosides and derivatives thereof that can be used as
small molecule ligands in the methods of the present inven-
tion. Compound 21 is 6'-N-5-hexynoate kanamycin A and
5 was used in selection experiments described herein. Com-
pound 21-FL is 21 conjugated to fluorescein via a Huisgen
dipolar cycloaddition reaction; the dye is indicated with the
ball. 21-FL was used in fluorescence assays to determine
dissociation constants. Kanamycin A, kanamycin B,
10 tobramycin, and neamine were used in competitive binding
experiments to determine aminoglycoside preferences for a
selected internal loop.
FIG. 8A is a schematic of the immobilization of 21 onto
15 azide-functionalized agarose slides via a Huisgen dipolar
cycloaddition reaction. FIG. 8B are representative autora-
diograms of (left) an array hybridized with radioactively
labeled 22 and (right) an array after excision of bound
RNAs. Bound RNAs can be amplified by RT-PCR, cloned,
20 and sequenced.
FIG. 9 is a drawing showing the sequence and structure of
oligonucleotides that can be used in the methods of the
present invention. Oligonucleotide 22 (SEQ ID NO:3) is an
RNA motif library (internal loop library) with six random-
25 ized positions (N). The library has 4096 unique members.
Oligonucleotides 23, 24, 25, and 26 are chase oligonucle-
otides. Oligonucleotide 23 is a duplex (SEQ ID NO:4 and
SEQ ID NO:5) that is a mimic of the stems of 22. The
sequence in 23 was altered such that it does not compete for
30 RT-PCR primers. Oligonucleotide 24 (SEQ ID NO:6) is a
mimic of the GAAA hairpin in 22. Oligonucleotides 25
(SEQ ID NO:7 and SEQ ID NO:8) and 26 (SEQ ID NO:9
and SEQ ID NO: 10) are DNA chase oligonucleotides that
35 ensure that interactions are RNA specific. The RNA 27 (SEQ
ID NO: 11) is the cassette in which the internal loop library
is embedded. Oligonucleotides 23-26 were used at 1000
times the concentration of 22 in selection experiments to
ensure that interactions occurred to loop nucleotides and not
40 to the cassette.
FIG. 10A is an image of an array after hybridization with
10 nM of 5' end 32P-labeled 22 and 10,000 nM each of chase
oligonucleotides 23-26. FIG. 10B is a dose-response curve
for binding to 21 in the presence of chase oligonucleotides
45 23-26 on the array. The extracted positions are circled. FIG.
10C shows the results from RT-PCR amplification of RNA
harvested from the array. The plus sign ("+") indicates RT
was added to the RT-PCR reaction. The minus sign ("-")
indicates RT was not added to the RT-PCR reaction. "PC"
5o refers to a positive control for RT-PCR. The aflinities of 21
for RNAs from position 1+ and 2+ are 65 nM and 11 nM,
respectively.
FIGS. 11A-11C relates to a two-dimensional combinato-
rial screen of an array-immobilized aminoglycoside library
55 for binding to members of 22. FIG. 11A is an image of an
array after hybridization with 32P-labeled 22 and unlabeled
23-26. Bound RNAs were mechanically removed from the
agarose surface at the positions indicated with the circle.
FIG. 11B shows the results from RT-PCR amplification of
60 the samples removed in A. "N.C." refers to a negative
control RT-PCR reaction from background or nonaminogly-
coside functionalized agarose. FIG. 11C shows structures of
the four azido-aminoglyco sides (28-31) that were anchored
onto alkyne-functionalized agarose and probed for binding
65 to the RNA library. By screening four compounds at five
loadings for binding 21, we probed 4x4096, or 16,382,
interactions in duplicate when we only consider the different
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compounds or 4x5x4096, or 81,920, interactions in dupli-
cate when we consider both the compounds and their
loadings.
FIG. 12 is a drawing showing the secondary structures of
the internal loops selected to bind 21. The secondary struc-
tures were the lowest free energy structures predicted by the
program RNAStructure (R8, R9). The nucleotides shown are
derived from the boxed region in 22 (FIG. 3). The selected
internal loops (library members) were: IL 21 (SEQ ID
NO:30), IL 22 (SEQ ID NO:31), IL 23 (SEQ ID NO:32), IL
24 (SEQ ID NO:33), IL 25 (SEQ ID NO:34), IL 26 (SEQ ID
NO:35), IL 27 (SEQ ID NO:36), IL 28 (SEQ ID NO:37), IL
29 (SEQ ID NO:38), IL 30 (SEQ ID NO:39), IL 31 (SEQ ID
NO:40), IL 32 (SEQ ID NO:41), IL 33 (SEQ ID NO:42), IL
34 (SEQ ID NO:43), IL 35 (SEQ ID NO:44), and IL 36
(SEQ ID NO:45). The dissociation constants (nM) were
determined from fluorescence assays. The Kd values for
oligonucleotides 22, 23, 24, 25+26, and 27 are 280 nM, >5
µM, >5 µM, >5 µM, and 1.3 µM, respectively. The Kd for
tRNA ph, is 0.7 µM. For each selected internal loop, the
binding curves indicate a stoichiometry of 1:1.
FIG. 13 shows secondary structure of the cassette with all
GU and mostAU pairs mutated to GC (32 (SEQ ID NO: 46))
used to determine if loop non-nearest neighbors contribute
to binding amity. The loop-closing base pairs were not
mutated since they have been shown to affect loop structure.
Oligonucleotide 33 (SEQ ID NO:47) is an RNA motif
library (internal loop library) based on the cassette 32 with
six randomized positions (N). The identities of 5 internal
loops embedded in cassette 32 are shown (i.e., IL 32 (SEQ
ID NO:48), IL 33 (SEQ ID NO:49), IL 34 (SEQ ID NO:50),
IL 35 (SEQ ID NO:51), IL 36 (SEQ ID NO:52)). The
dissociation constants for the loops in the mutated cassette
are directly below the loop number and are reported in
nanomoles per liter. The dissociation constants when the
loops are displayed in 22 are in parentheses.
DETAILED DESCRIPTION OF THE
INVENTION
The present invention relates to a method for identifying
a nucleic acid motif which interacts with a ligand. The
method includes providing a plurality of ligands immobi-
lized on a support, wherein each particular ligand is immo-
bilized at a discrete location on the support; contacting the
plurality of immobilized ligands with a nucleic acid motif
library under conditions effective for one or more members
of the nucleic acid motif library to bind with the immobi-
lized ligands; and identifying members of the nucleic acid
motif library that are bound to a particular immobilized
ligand.
"Nucleic acid", as used herein, is meant to refer to RNA
and DNA. "RNA", as used herein, is meant to refer to
ribonucleic acid molecules and oligomers. "DNA", as used
herein, is meant to refer to deoxyribonucleic acid molecules
and oligomers.
"Nucleic acid motif', as used herein, is meant to refer to
a targetable internal loop, hairpin loop, bulge, or other
targetable nucleic acid structural motifs. "Nucleic acid
motif' are meant to include RNA motifs, for example, as
described in Batey et al., "Tertiary Motifs in RNA Structure
and Folding," Angew. Chem. Int. Ed., 38:2326-2343 (1999),
which is hereby incorporated by reference. Examples of
RNA motifs include symmetric internal loops, asymmetric
internal loops, 1x1 internal loops, 1x2 internal loops, 1x3
internal loops, 2x2 internal loops, 20 internal loops, 2x4
internal loops, 30 internal loops, 3x4 internal loops, 4x4
T
internal loops, 4x5 internal loops, 5x5 internal loops, 1 base
bulges, 2 base bulges, 3 base bulges, 4 base bulges, 5 base
bulges, 4 base hairpin loops, 5 base hairpin loops, 6 base
hairpin loops, 7 base hairpin loops, 8 base hairpin loops, 9
5 base hairpin loops, 10 base hairpin loops, multibranch loops,
pseudoknots, etc. Examples of DNA motifs include sym-
metric internal loops, asymmetric internal loops, bulges, and
hairpin loops.
"Ligand", as used herein, is meant to refer to non-nucleic
io acid compounds that may be capable of binding to or
otherwise interacting with one or more nucleic acids or
nucleic acid motifs. Examples of ligands include proteins,
polypeptides, carbohydrates, and other non-nucleic acid
biopolymers; whole cells; and small molecules. "Small
15 molecules", as used herein, are meant to refer to non-
biopolymer compounds having, for example, a molecular
weight of less than 10,000 grams/mole, such as less than
9000 grams/mole, less than 8000 grams/mole, less than 7000
grams/mole, less than 6000 grams/mole, less than 5000
20 grams/mole, less than 4000 grams/mole, less than 3000
grams/mole, less than 2000 grams/mole, less than 1000
grams/mole, less than 900 grams/mole, less than 800 grams/
mole, less than 700 grams/mole, less than 600 grams/mole,
less than 500 grams/mole, less than 400 grams/mole, etc.)
25 that may be capable of binding to or otherwise interacting
with one or more nucleic acids or nucleic acid motifs.
Examples of small molecules that can be used in the
methods of the present invention include small molecule
antibiotics, small molecule antiviral agents, small molecule
3o antifungals, small molecule chemotherapeutic s, and other
small molecule drugs. The small molecules can be biological
compounds or mixtures of such compounds (e.g., derived
from plant, fungal, bacterial, algal, or other extracts); or they
can be synthetic organic compounds; or they can be inor-
35 ganic compounds (e.g., cisplatin). Pharmaceutical compa-
nies have extensive libraries of such small molecules that
can be used in the methods of the present invention.
"Interacts", as used herein, is mean to refer to binding or
other stabilized association between the ligand and the RNA
40 motif. The association can be thermodynamically stabilized
or kinetically stabilized or both, and the interaction can be
the result of covalent bonding, hydrogen bonding, van der
Waals interactions, electrostatic interactions, or combina-
tions of these and/or other types of interactions.
45 The method includes providing a plurality of ligands
immobilized on a support, each particular ligand being
immobilized at a discrete location on the support. Illustra-
tively, the ligands can be immobilized on the support's
surface at discrete locations arranged in the form of an array.
5o The choice of support is not particularly critical to the
practice of the present invention. Agarose supports are
suitable and, in some embodiments, may be optimal. Other
suitable supports include sepharose supports, functionalized
glass supports, polyacylamide supports, polylactic acid sup-
55 ports, polymaleic acid supports, and other solid supports.
Ligands can be immobilized, for example, using standard
immobilization chemistries, the selection of which will
depend on the nature of the ligands being immobilized and
the nature of the support. Such immobilization chemistries
60 can involve covalently coupling the small molecule or other
ligand to the support. For example, in cases where the
support is an agarose support, the support can be function-
alized with azide and alkyne-functionalized small molecules
or other ligands can be immobilized via a Huisgen dipolar
65 cycloaddition reaction. By way of further illustration, in
cases where the ligands are small molecules or other ligands
functionalized with azide moieties, immobilization can be
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effected using an alkyne-functionalized agarose support.
Other chemistries can be employed, such as using silyl
chloride functionalized supports to immobilize alcohol-con-
taining small molecules, maleimide functionalized supports
to immobilize thiol-containing small molecules. While the
foregoing discussion has focused on immobilization via
coupling the ligand to the support, other methods of immo-
bilization can be used. For example, the ligands can be
immobilized as a solution-phase chemical microarray (such
as where the ligands are immobilized in wells or in which
the ligands are immobilized as discrete droplets which are
then contacted with the nucleic acid motif library using
aerosol deposition technology) or as a dry chemical microar-
ray.
As noted above, a plurality of ligands are immobilized on
the support. In certain embodiments, at least 4 ligands are
immobilized on the support. In certain embodiments, at least
10 ligands are immobilized on the support. In certain
embodiments, at least 20 (e.g., at least 30, at least 40, at least
50, a least 60, at least 80, at least 100, at least 150, at least
200, etc.) ligands are immobilized on the support. Some or
all of the ligands that are immobilized on the support can be
structurally related, as in the case where some or all of the
ligands that are immobilized on the support are congeners of
one another.
The plurality of ligands are generally immobilized at the
same loading, although this need not be the case. Suitable
ligand loadings are from about 1 femptomole to about 100
nanomoles (such as from about 100 femptomoles to about
10 nanomoles and/or from about 1 picomole to about 1
nanomole) of ligand per discrete location.
In certain embodiments, at least one of the particular
ligands is present at two or more different loadings, the two
or more different loadings being immobilized at separate,
discrete locations on the support. In certain embodiments,
each of the particular ligands is present at two or more
different loadings, the two or more different loadings being
immobilized at separate, discrete locations on the support. In
certain embodiments, at least one of the particular ligands is
present at four or more different loadings, the four or more
different loadings being immobilized at separate, discrete
locations on the support. In certain embodiments, each of the
particular ligands is present at four or more different load-
ings, the four or more different loadings being immobilized
at separate, discrete locations on the support. Where two or
more different loadings (e.g., 2, 3, 4, 5, 6, etc. different
loadings) are employed for a particular ligand, the different
loadings can be effected by serial dilution (e.g., as in the case
where the first loading is x, the second loading is x/2, the
third loading is x/4, the fourth loading is x/8, the fifth
loading is x/16, etc.).
As noted above, the methods of the present invention
further include contacting the plurality of immobilized
ligands with a nucleic acid motif library under conditions
effective for one or more members of the nucleic acid motif
library to bind with the immobilized ligands.
In certain embodiments, the nucleic acid motif library is
an RNA motif library. In certain embodiments, the nucleic
acid motif library is a DNA motif library.
The nucleic acid motif library (e.g., RNA motif library,
etc.) can include at least 4 members, such as in cases where
the nucleic acid motif library includes at least 10 members,
at least 20 members, at least 40 members, at least 60
members, at least 80 members, at least 100 members, at least
200 members least 500 members, at least 1000 members, at
least 2000 members, at least 3000 members, at least 4000
members, etc. In certain embodiments, the nucleic acid
8
motif library will contain members that differ from one
another in the identity of the bases (i) in the nucleic acid
motif and/or (ii) in the region near the nucleic acid motif
(e.g., adjacent to the nucleic acid motif).
5 Illustratively, in certain embodiments, the method of the
present invention is being used to identify an RNA motif
which interacts with a ligand, and an RNA motif library is
employed. For example, the RNA motif library can be an
RNA internal loop library whose members differ from one
io another (i) in the identity of the bases in the RNA internal
loop and/or (ii) in the identity of the base pairs adjacent to
the RNA internal loop (the so-called loop closing base
pairs). The RNA motif library can be, for example, a
symmetric internal loop library, an asymmetric internal loop
15 library, a 1x1 internal loop library, a 1x2 internal loop
library, a 1x3 internal loop library, a 2x2 internal loop
library, a 2x3 internal loop library, a 2x4 internal loop
library, a 3x3 internal loop library, a 3x4 internal loop
library, a 4x4 internal loop library, a 4x5 internal loop
20 library, a 5x5 internal loop library, a 1 base bulge library, a
2 base bulge library, a 3 base bulge library, a 4 base bulge
library, a 5 base bulge library, a 4 base hairpin loop library,
a 5 base hairpin loop library, a 6 base hairpin loop library,
a 7 base hairpin loop library, an 8 base hairpin loop library,
25 a 9 base hairpin loop library, a 10 base hairpin loop library,
a multibranch loop library, a pseudoknot library, etc. Com-
binations of these and other RNA motif libraries can be used.
For completeness, it may be desirable to employ an RNA
motif library which includes all possible combinations of
3o bases (e.g., an 30 internal loop library containing 1600
different 30 internal loops). The members of the RNA
motif library can further include (i.e., in addition to the
variable RNA motif region) RNA regions that do not vary
from member to member (e.g., invariant stem regions,
35 invariant hairpin loop regions, etc.). Suitable RNA motif
libraries can be prepared by conventional transcription tech-
niques (e.g., those employing T7 RNA polymerase, as
described, for example, in Milligan et al., "Synthesis of
Small RNAs Using T7 RNA Polymerase," Methods Enzy-
40 mol., 180:51-62 (1989), which is hereby incorporated by
reference) from DNA templates, such as DNA templates that
are commercially available from Integrated DNA Technolo-
gies (Coralville, Iowa)).
By way of further illustration, in certain embodiments, the
45 method of the present invention is being used to identify a
DNA motif which interacts with a ligand, and a DNA motif
library is employed. For example, the DNA motif library can
be a DNA internal loop library whose members differ from
one another (i) in the identity of the bases in the DNA
50 internal loop and/or (ii) in the identity of the base pairs
adjacent to the DNA internal loop (the so-called loop closing
base pairs). The DNA motif library can be, for example, a
symmetric internal loop library, an asymmetric internal loop
library, a bulge library, a hairpin loop library, etc. Combi-
55 nations of these and other DNA motif libraries can be used.
For completeness, it may be desirable to employ a DNA
motif library which includes all possible combinations of
bases. The members of the DNA motif library can further
include (i.e., in addition to the variable DNA motif region)
6o DNA regions that do not vary from member to member (e.g.,
invariant stem regions, invariant hairpin loop regions, etc.).
In certain embodiments, at least 4 ligands are immobi-
lized on the support, and the nucleic acid motif library (e.g.,
the RNA motif library, the DNA motif library, etc.) includes
65 at least 100 members. In certain embodiments, at least 10
ligands are immobilized on the support, and the nucleic acid
motif library (e.g., the RNA motif library, the DNA motif
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library, etc.) includes at least 100 members. In certain
embodiments, at least 10 ligands are immobilized on the
support, and the nucleic acid motif library (e.g., the RNA
motif library, the DNA motif library, etc.) includes at least
1000 members. 5
In certain embodiments, the ligand is a small molecule,
the nucleic acid motif is a DNA motif, and the nucleic acid
motif library is a DNA motif library. In certain embodi-
ments, the ligand is a small molecule, the nucleic acid motif
is a DNA motif, the nucleic acid motif library is a DNA io
motif library, at least 10 ligands are immobilized on the
support, and the DNA motif library includes at least 100
members. In certain embodiments, the ligand is a small
molecule, the nucleic acid motif is an RNA motif, and the
nucleic acid motif library is an RNA motif library. In certain 15
embodiments, the ligand is a small molecule, the nucleic
acid motif is an RNA motif, the nucleic acid motif library is
an RNA motif library, at least 10 ligands are immobilized on
the support, and the RNA motif library includes at least 100
members. 20
The plurality of immobilized ligands can be contacted
with the nucleic acid motif library (e.g., the RNA motif
library, the DNA motif library, etc.) by a variety of methods.
For example, the nucleic acid motif library can be dissolved
or suspended in a suitable solvent, buffer, or buffer system, 25
and the immobilized ligands can be pre-equilibrated with a
suitable hybridization buffer. The nucleic acid motif library
can then be applied to the immobilized ligands, for example,
by distributing the nucleic acid motif library evenly over the
array surface; and the immobilized ligands and nucleic acid 30
motif library can be incubated with one another for a period
of time and at a temperature effective for one or more
members of the nucleic acid motif library to bind with the
immobilized ligands, such as, for example, at from about 15°
C. to about 35° C. (e.g., at from about 20° C. to about 30° 35
C. and/or at about room temperature) for from about 5
minutes to about 2 hours (e.g., from about 15 minutes to
about 1 hour and/or for about 30 minutes). Even distribution
can be effected by placing an inert film (e.g., a piece of
PARAFILMTM) over the applied solution, and the film can 40
be left in place during incubation.
As noted above, the methods of the present invention
further include identifying the members of the nucleic acid
motif library (e.g., the RNA motif library, the DNA motif
library, etc.) that are bound to a particular immobilized 45
ligand. This can be carried out by harvesting members of the
nucleic acid motif library that are bound at the discrete
location on the support corresponding to the particular
immobilized ligand. Harvesting can be carried out by any
suitable technique, such as by direct excision. The harvested 50
members of the nucleic acid motif library can then be
cloned, RT-PCR amplified, and sequenced, using conven-
tional techniques, such as those described in the Examples
section of the present application.
The methods of the present invention can include addi- 55
tional steps. For example, in certain embodiments, the
method the present invention can further include incubating
the plurality of immobilized ligands with one or more chase
oligonucleotides. "Chase oligonucleotides", as used herein,
are meant to include oligonucleotides that are designed to 60
ensure that the ligand interacts with the nucleic acid motif
(i.e., with the nucleic acid motif library's variable region)
and not with those nucleic acid regions that do not vary from
member to member (e.g., invariant stem regions, invariant
hairpin loop regions, etc.). The design of such stem chase 65
and hairpin oligonucleotides will depend on the sequences
used in the nucleic acid regions that do not vary from
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member to member, for example, as described in the
Examples section of the present application. "Chase oligo-
nucleotides", as used herein, are also meant to include DNA
chase oligonucleotides (i.e., oligonucleotides that are meant
to ensure that the interactions are RNA specific). Example of
suitable DNA chase oligonucleotides include duplex AT
decamers, duplex CG decamers, and combinations thereof.
In certain embodiments, the one or more chase oligonucle-
otides includes stem chase oligonucleotides. In certain
embodiments, the one or more chase oligonucleotides
includes hairpin chase oligonucleotides. In certain embodi-
ments, the one or more chase oligonucleotides includes
DNA chase oligonucleotides. Combinations of these and
other chase oligonucleotides can be employed, for example
as in the case where the one or more chase oligonucleotides
includes stem chase oligonucleotides, hairpin chase oligo-
nucleotides, and DNA chase oligonucleotides.
Incubation with the one or more chase oligonucleotides is
carried out prior to the step identifying members of the
nucleic acid motif library (e.g., the RNA motif library, the
DNA motif library, etc.) that are bound to a particular
immobilized ligand; and incubation with the one or more
chase oligonucleotides can be carried out, for example,
subsequent to and/or concurrently with the step of contact-
ing the plurality of immobilized ligands with the nucleic
acid motif library. Typically, the chase oligonucleotides are
employed at a concentration substantially greater than that
of the nucleic acid motif library, such as at a concentration
that is at least 10 times (e.g., at least 20 times, at least 50
times, at least 100 times, at least 200 times, at least 500
times, at least 1000 times, about 1000 times, etc.) the
concentration of the nucleic acid motif library.
Using the aforementioned methods of the present inven-
tion, ligands which interact with particular nucleic acid
motifs (e.g., with particular RNA motifs, with particular
DNA motifs, etc.) can be identified. Since the nucleic acid
sequences of many biologically important nucleic acid mol-
ecules are known, one can readily ascertain which biologi-
cally important nucleic acid molecules have the particular
nucleic acid motifs with which a particular ligand interacts.
Accordingly, the present invention can be used to identify
ligands that bind or otherwise interact with biologically
important nucleic acid molecules. Such ligands can be used
to target such biologically important nucleic acid molecules,
for example, for diagnostic or therapeutic purposes. In
certain embodiments, such ligands can contain or otherwise
be coupled to a probe moiety (e.g., a flourescent moiety) for
identifying the presence (or quantifying the amount) of a
particular nucleic acid in a sample. In certain embodiments,
such ligands can contain or otherwise be coupled to a moiety
that affects a particular nucleic acid's function (e.g., by
affecting the nucleic acid's structure, by cleaving the nucleic
acid molecule, etc.) for use as a therapeutic agent.
Ligand-nucleic acid motif interactions (e.g., ligand-RNA
motif interactions, ligand-DNA motif interactions, etc.)
identified in accordance with the methods of the present
invention can also be used to design new molecules which
target such biologically important nucleic acid molecules.
For example, if, upon examination of a biologically impor-
tant RNA molecule, it is determined that the biologically
important RNA molecule contains two RNA motifs (e.g.
Motif A and Motif B) in close proximity to one another and
if, using the methods of the present invention, Ligand X was
found to bind with Motif A and Ligand Y was found to bind
with Motif B, one can design a new molecule, X Z Y
(where Z represents a linking moiety), for targeting the
biologically important RNA molecule.
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The information regarding ligand-nucleic acid motif inter-
actions (e.g., ligand-RNA motif interactions, ligand-DNA
motif interactions, etc.) derived using the methods of the
present invention can be assembled into a database. Such
databases can then be used in methods for selecting, from a 5
plurality of candidate ligands, one or more ligands that have
increased likelihood of binding to a nucleic acid molecule
having a particular nucleic acid motif (e.g., an RNA mol-
ecule having a particular RNA motif, a DNA molecule
having a particular DNA motif, etc.). Such methods can l0
include providing a database which correlates various
ligands' abilities to bind to the particular nucleic acid motif
and various other nucleic acid motifs (for example, in
accordance with the methods of the present invention); 15
comparing the candidate ligands' ability to bind to the
particular nucleic acid motif; and choosing one or more
ligands based on their ability to bind to the particular nucleic
acid motif.
In certain situations, it may be desirable to select ligands 20
which bind to one nucleic acid molecule but which do not
bind to another nucleic acid molecule (e.g., ligands which
bind to one RNA molecule but which do not bind to another
RNA molecule, ligands which bind to one DNA molecule
but which do not bind to another DNA molecule, etc.). The 25
aforementioned databases can be used to make such selec-
tions. For example, such databases can be used in methods
for selecting, from a plurality of candidate ligands, one or
more ligands that have increased likelihood of binding to a
first nucleic acid molecule comprising a first particular 30
nucleic acid motif and that have decreased likelihood of
binding to a second nucleic acid molecule comprising a
second particular nucleic acid motif. Such methods can
include providing a database which correlates various
ligands' abilities to bind to the first particular nucleic acid 35
motif, to the second particular nucleic acid motif, and to
various other nucleic acid motifs (for example, in accor-
dance with the methods of the present invention); comparing
the candidate ligands' ability to bind to the first particular
nucleic acid motif and to the second particular nucleic acid 40
motif; and choosing one or more ligands based on their
ability to bind to the first particular nucleic acid motif and
their inability to the second particular nucleic acid motif.
The first particular nucleic acid motif can be an RNA motif,
and the second particular nucleic acid motif can be a DNA 45
motif; the first particular nucleic acid motif can be a DNA
motif, and the second particular nucleic acid motif can be an
RNA motif; both the first and second particular nucleic acid
motifs can be RNA motifs; or both the first and second
particular nucleic acid motifs can be DNA motifs. 50
The present invention also relates to a method for iden-
tifying a nucleic acid which interacts with a ligand. The
method includes providing a plurality of ligands immobi-
lized on a support, wherein each particular ligand is immo-
bilized at a discrete location on the support; contacting the 55
plurality of immobilized ligands with a nucleic acid library
under conditions effective for one or more members of the
nucleic acid library to bind with the immobilized ligands;
and identifying members of the nucleic acid library that are
bound to a particular immobilized ligand. 60
Suitable methods for providing a plurality of ligands
immobilized on a support include those which have been
disclosed hereinabove. For example, suitable ligands which
can be used in connection with this aspect of the present
invention include proteins, polypeptides, carbohydrates, and 65
other non-nucleic acid biopolymers; whole cells; and small
molecules, such as those discussed hereinabove.
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Suitable methods for contacting the plurality of immobi-
lized ligands with a nucleic acid library; suitable conditions
effective for one or more members of the nucleic acid library
to bind with the immobilized ligands; and suitable ways to
identify members of the nucleic acid library that are bound
to a particular immobilized ligand include those methods
and conditions which were discussed hereinabove in the
context of contacting the plurality of immobilized ligands
with nucleic acid motif libraries and in the context of
identifying member(s) of the nucleic acid motif library that
are bound to a particular immobilized ligand.
The nucleic acid library (e.g., an RNA or DNA library)
can include at least 4 members, such as in cases where the
nucleic acid library includes at least 10 members, at least 20
members, at least 40 members, at least 60 members, at least
80 members, at least 100 members, at least 200 members
least 500 members, at least 1000 members, at least 2000
members, at least 3000 members, at least 4000 members,
etc. In certain embodiments, the nucleic acid library will
contain members that differ from one another in the identi-
ties of the bases in a particular region of the nucleic acid
molecule (e.g., in a region containing from about 10 to about
40 bases, such as in a region containing from about 10 to
about 35 bases, from about 10 to about 30 bases, from about
10 to about 25 bases, from about 10 to about 20 bases, from
about 10 to about 15 bases, from 10 to 15 bases, 10 bases,
11 bases, 12 bases, 13 bases 14 bases, etc.), the remainder of
the nucleic acid molecule being the same or substantially the
same amongst the members of the nucleic acid library. The
variable region can, but need not, contain structural motif(s);
and if the variable region does contain structural motif(s),
the ligand-nucleic acid molecule binding can, but need not
occur at or otherwise involve the bases in the structural
motif(s). As indicated above, the members of the nucleic
acid library can have invariant regions. In certain embodi-
ments, the variable region contains more bases than the
invariant region. In certain embodiments, the invariant
region contains about 40 bases or fewer, such as about 30
bases or fewer, about 20 bases or fewer, 10 bases or fewer,
between about 10 and about 40 bases, between about 10 and
about 20 bases, etc. In certain embodiments, the nucleic acid
library is an X-mer nucleic acid library, wherein X is from
about 10 to about 40, such as from about 10 to about 35,
from about 10 to about 30, from about 10 to about 25, from
about 10 to about 20, from about 10 to about 15, from 10 to
15, 10, 11, 12, 13, 14, etc.).
Illustratively, in certain embodiments, the method of the
present invention is being used to identify an RNA which
interacts with a ligand, and an RNA library is employed. For
example, the RNA library can be a 10-mer to 40-mer RNA
library, such as a 10-mer to 15-mer RNA library. By way of
further illustration, in certain embodiments, the method of
the present invention is being used to identify a DNA which
interacts with a ligand, and a DNA library is employed. For
example, the DNA library can be a 10-mer to 40-mer RNA
library, such as a 10-mer to 15-mer DNA library.
For completeness, it may be desirable to employ a nucleic
acid library (e.g., a RNA library or a DNA library) which
includes all possible combinations of bases in the variable
region.
In certain embodiments, at least 4 ligands are immobi-
lized on the support, and the nucleic acid library (e.g., the
RNA library, the DNA library, etc.) includes at least 100
members. In certain embodiments, at least 10 ligands are
immobilized on the support, and the nucleic acid library
(e.g., the RNA motif library, the DNA library, etc.) includes
at least 100 members. In certain embodiments, at least 10
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ligands are immobilized on the support, and the nucleic acid
library (e.g., the RNA library, the DNA library, etc.) includes
at least 1000 members.
Using the method of the present invention, nucleic acid(s)
which interacts with a ligand can be identified. The nucleic
acids (e.g., the RNA, the DNA, etc.) thus identified can be
used to target the ligand. Illustratively, the nucleic acid can
be coupled to a fluorescent or other probe and used to detect
the presence (or quantify the amount or determine the
location) of the ligand that may be present in a sample, such
as a biological sample, a tissue sample, a blood sample, a
urine sample, a cell sample, or in an organism.
The present invention is further illustrated by the follow-
ing non-limiting examples.
EXAMPLES
Example 1 Using Selection to Identify and
Chemical Microarray to Study the RNA Internal
Loops Recognized by Kanamycin A: Overview
In this Example 1 and in the following Examples 2-3, we
describe our initial steps towards constructing a database of
RNA-small molecule binding partners to aid rational design
of compounds that target RNA. In order to do so, we have
developed a selection-based approach that requires only a
single round of selection to identify the RNA secondary
structural elements (internal loops, hairpins, and bulges, for
example) that bind small molecules. By screening RNA
secondary structure libraries, we increase the chances of
finding library members in a large biologically active RNA,
such as rRNA. This is in contrast to Selective Exponential
Enrichment (SELEX) experiments [53, 54] that have iden-
tified RNAs ranging from 17-mers to 30-mers that bind
ligands with high amity and specificity. Although the
SELEX/aptamer approach finds high amity RNA-ligand
partners, it is unlikely to find these aptamers in a larger,
biologically active RNA. In our initial study, we have
screened a 4096 member RNA 30 internal loop library for
binding to kanamycin A that is immobilized through the 6'
amino group onto sepharose resin. We identified an
ensemble of structures that binds the aminoglycoside and
have scored their relative amities using a microarray-based
method. The highest affinity structures have 5'UU/3'UC 2x2
internal loops closed by A-U pairs.
Further details regarding the experiments described in this
Example 1 and in the following Examples 2-3 can be found
in Disney et al. "Using Selection to Identified and Chemical
Microarray to Study the RNA Internal Loops Recognized by
6'-N-Acylated Kanamycin A," ChemBioChem, 8(6):649-
656 (2007) and in the associated Supporting Infor-mation
(available on the internet at www.wiley-vch.de/contents/
jc2268/2007/11600569 s.pdf) which are hereby incorporated
by reference.
Example 2 Using Selection to Identify and
Chemical Microarray to Study the RNA Internal
Loops Recognized by Kanamycin A: Results and
Discussion
Selection of the RNA Internal Loops that Bind Kanamy-
cin A.
Selection experiments were completed with kanamycin A
(FIG. 1A, compound 1) immobilized onto sepharose resin
and an RNA 30 internal loop library embedded in a hairpin
cassette (RI, FIG. 2). This library was designed from a
sequence used by others to identity RNA motifs that have
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interesting thermodynamic properties [34, 55]. Features of
the library include an ultrastable GAAA (GNRA-type) hair-
pin [56] to facilitate proper folding and single stranded
primer binding sites for amplification via RT-PCR Kanamy-
5 cin A was used in our initial study because it is a known
RNA-binding ligand and it has been shown to bind non-
canonically paired RNAs like those displayed in the random
region of our library. Additionally, this ligand has been
immobilized onto resin and used for selection experiments
io [54, 57].
A large excess of kanamycin A relative to the loading of
succinimide esters on the sepharose was used to preferen-
tially immobilize the ligand at the 6' NH2 position, which is
the most nucleophilic. It should be noted that when kanamy-
15 cin A is acetylated at the 6' position, binding to an oligo-
nucleotide mimic of the bacterial A-site is reduced several
orders of magnitude relative to the parent aminoglycoside
[47]. The reduction in binding amity is due to elimination
of important contacts that the 6' amino group forms with the
20 A-site [11, 12, 58]. Therefore, we have challenged our
system to find 6' acetylated kanamycin A-RNA secondary
structural partners by using the modified aminoglycoside as
bait to pull down members of the 3x3 internal loop library.
The 6' NHz group has the potential to be used in future
25 experiments as a reactive group for conjugation to link small
molecule modules together to target a larger RNA.
Selections were completed by incubating a solution that
contained 5' end 32P-labeled RI in buffer with resin-immo-
bilized kanamycin A. In addition to RL a variety of other
30 oligonucleotides were added to the incubation solution (R2-
R4, DI, D2). We found that on average only 150 members
(-4%) of the 4096-member 3x3 internal loop library bound
to immobilized kanamycin A based on the percentage of the
initial radioactivity that eluted with kanamycin A. This
35 suggested that we did not have to increase the stringency of
our selection by adding higher concentrations of chase
oligonucleotides R2-R4, DI, and D2 and that the random
regions in the library are being recognized. The small
number may be due to the manner in which the ligand was
40 immobilized onto the resin (impairs the Camino group from
forming stabilizing contacts with RNA).
Selected RNAs were amplified via RT-PCR, cloned into a
vector, and sequenced. The secondary structures of the
selected RNAs were predicted by the RNA secondary struc-
45 ture prediction program RNAStructure [8]. A variety of
structures were identified including six 1x1 internal loops
half of which contain a C residue opposite a U residue, seven
2x2 loops with IL 1 and IL 2 having the same loop sequence
but different orientation of a closing base pair, and five 3x3
50 loops (FIG. 3).
Studying the Binding of Selected RNA Internal Loops to
Kanamycin A.
To score the binding affinity of each RNA internal loop,
we developed an array-based method to determine relative
55 affinities quickly. Microarrays have been used in a variety of
experiments to probe the affinities of protein and RNA to
small molecules in a rapid and highly parallel manner
requiring minimal amounts of the analyte and ligand [28-29,
59-61]. To complete microarray-based affinity experiments
60 with kanamycin A, we required a kanamycin A derivative
that could be selectively immobilized onto an array surface.
We envisioned that 6'-N-5-hexynoate kanamycin A (FIG.
1A, compound 2) would allow for defined immobilization
via reaction of the alkyne handle with azide-displaying glass
65 slides a using Huisgen dipolar cycloaddition reaction, or
"click chemistry" [39]. The synthesis of 2 was completed as
illustrated in the scheme presented in FIG. 1B. We used
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1,3,3'-tri-N-(tert-butyl dicarbonyl) kanamycin A (3) [62] as
the starting material in the synthesis since all amines except
for the one at the 6' position are protected as acid-labile Boc
groups. Compound 3 was reacted with N-succinimidyl-5-
hexynoate to afford 4 in 65% yield. This compound was
deprotected with trifluoracetic acid in 76% yield to afford the
final product (2). A neamine derivative was also synthesized
using the same synthetic sequence and was subsequently
labeled with fluorescein by reaction with fluorescein isoth-
iocyanate.
Fluorescein-labeled 6'-N-hexynoate neamine (neamine-
Fl) was synthesized to test click chemistry immobilization
conditions because the fluorescent signal allowed a direct
readout of surface loading (FIGS. 4A and 413). A solution of
neamine-Fl was spotted onto azide-displaying agarose
slides, and reactions were completed in the presence or
absence of each reagent required for reaction. Loading of the
labeled neamine-Fl onto the slide surface was only observed
when all of the click chemistry reagents were added (sodium
ascorbate, CuSO4, and TBTA ligand). Signals that approach
background were observed when any one of the reagents
was removed from the spotting solution. These results
indicate that 6' hexynoate neamine-Fl is reacting with the
surface via triazole formation. We observe similar results
when 6'-N-5-hexynoate kanamycin A is immobilized and
then probed for binding to a radioactively labeled selected
RNA.
Typically microarray experiments can be used to probe
the binding of a variety of small molecules to a single or a
few analytes at once. In order to increase the number of
conditions that can be probed on a single array, we affixed
a silicon gasket that created 50 microwells on the surface of
each chip (FIG. 5A). These microwells converted the array
into a miniaturized 50-well plate that is easily functionalized
to display kanamycin. Compound 2 was immobilized in
each microwell at a constant concentration. Binding experi-
ments were completed by delivering 10 µL of a solution
containing serially diluted concentrations of the internal
loop of interest and trace 5'end 32p labeled IL 7 into each
microwell. Dose response curves were constructed and fit to
determine the concentration of competitor that inhibited
50% of the binding of the radioactively labeled RNA (FIG.
3, FIG. 513, and FIG. 5C). FIG. 5B is a representative
autoradiogram for binding selected RNAs relative to binding
of control oligonucleotides R2, R3, Dl and D2, and R4, the
cassette without an internal loop. All selected loops have at
least a >20-fold lower ICso than tRNA or any of the control
oligonucleotides used (FIG. 3). tRNA has approximately
twice the number of nucleotides as our loop library, and its
weak affinity for kanamycin A suggests that binding to the
loops is not due to forming non-specific electrostatic con-
tacts to the phosphodiester backbone. Moreover, each of the
selected RNAs binds more tightly to kanamycin A than the
entire library (RI) which has an ICso of 110 nM. These
results suggest that our method selects for specific RNA
internal loop-ligand interactions and eliminates the selection
of weaker binders.
The two highest affinity sequences, IL 1 and IL 2, have
ICso's of 2.2 and 3.3 nM, respectively. Both are 5'UU/3'UC
2x2 loops but they differ in the orientation of one of the
closing A-U pairs. It is interesting to note that for tandem
G•A pairs the orientation of the closing base pairs dramati-
cally affects the structure of the internal loops formed. [45,
46] It appears that is not the case when a single pair in IL 1
and IL 2 is changed based on this data. The five highest
affinity binders (IL 1-5) contain two U's in the same position
on opposite sides of the loop (FIG. 3). IL 18 also displays
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this sequence pattern; however, the U's are flanked by
purines. It is possible that their presence affects loop struc-
ture or dynamics and is the cause of decreased affinity. If one
of the U's on opposite sides of the loop in IL 1 and IL 2 is
5 replaced with a C and the closing base pair is changed from
AU to GC, the resulting loop, IL 17, binds —10-fold weaker.
This suggests that the aminoglcoside is forming contacts
with loop nucleotides and/or the closing base pair or that the
structure of the loop is altered when the nucleotides are
to mutated.
The binding site of 2 was determined by enzymatic
probing of IL 7 and R4 in the presence or absence of 2 with
RNase A and Sl nuclease. Results show that only nucleo-
tides in the loop and the surrounding base pairs in IL 7 are
protected from cleavage. No nucleotides in the cassette R4
15 are protected (FIGS. 6A and 613). These results coupled with
the relative binding measurements further suggest that we
have selected specific RNA internal loop-small molecule
partners. We have also observed decreased modification by
diethyl pyrocarbonate ("DEPC") of loop nucleotides in IL 1
20 and IL 16 when 2 is present. DEPC has been shown to
modify U's at slightly basic pH [63, 64].
A variety of biologically important RNAs bind amino-
glycosides including the A-site in bacterial ribosomes [65,
66], and TAR [67] and REV [68] RNAs from HIV. Aptamers
25 to tobramycin and kanamycin have also been selected [54,
57]. Interestingly, the aptamers for kanamycin and tobramy-
cin, [54, 57] TAR RNA, [67] and the A-site [11, 58, 65] all
have unpaired U's in the sites that bind to the aminoglyco-
side. The consensus region in one tobramycin aptamer
30 
contains a ten nucleotide hairpin in which four of the hairpin
nucleotides are U's [54]. In TAR RNA, two of the three
nucleotides in the bulge that binds tobramycin are U's, and
there is a 1x1 U•U internal loop in the A-site in bacterial
ribosomes. Structural studies of aminoglycosides bound to
the A-site show that the aminoglycoside forms direct con-
35 tacts to the U•U pair (U1406•UI495) through the 2-deox-
ystreptamine ring common to all aminoglycosides [58].
Based on these studies it is clear that the aminoglycosides
bind to a wide array of non-canonically paired RNA struc-
tures, with a preference for U. This may be due to the
40 conformational flexibility of aminoglycosides, allowing
them to fit into a variety of RNA folds [69]. Taken together
with our study, these collective data suggest that aminogly-
cosides prefer RNAs that have non-canonically paired or
unpaired U's. We have identified a consensus 2x2 RNA
45 internal loop sequence displaying unpaired or non-canoni-
cally paired U's that binds 6'acetylated kanamycin A. These
results further our understanding of the RNA internal loops
bound by ligands and may also give insight into off-target
effects when aminoglycosides bind to bystander RNAs. This
50 
information could aid design of less toxic aminoglycosides.
In this Example 2 and in related Examples 1 and 3, we
have described the development of two methods to quickly
identify RNA-small molecule partners and to quickly score
their relative affinities. Results from this study represents out
first entry into constructing a database of small molecule-
55 RNA secondary structural motif interactions. This rational
approach has the potential to allow more efficient identifi-
cation of lead small molecules that modulate RNA structure
and function.
60 Example 3 Using Selection to Identify and
Chemical Microarray to Study the RNA Internal
Loops Recognized by Kanamycin A: Materials and
Methods
65 This Example 3 describes the materials and methods that
were used in carrying out the experiments described in
Example 2.
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Selection and Nucleic Acid Synthesis. General Methods.
Nanopure water was used in all experiments. All solutions
for buffers were prepared with DEPC-water to insure the
absence of nucleases. All DNA oligonucleotides were pur-
chased from Integrated DNA Technologies ("IDT") Coral-
ville, Iowa) and were purified by denaturing 17% PAGE.
DNAs were visualized by UV shadowing, and the products
were extracted from the gel slice by tumbling overnight in
sterile 0.3 M NaCl at 4° C. tRNA XSA from Baker's yeast
used in the microarray binding experiments was purchased
from Sigma-Aldrich. N-hydroxyl succinimide-activated
sepharose was purchased from Amersham. Reverse tran-
scriptase was obtained from Life Sciences, Inc. (St. Peters-
burg, Fla.). Oligonucleotide extinction coefficients were
determined on the HYTHERTM server available from the
SantaLucia laboratory (HYTHERTM version 1.0, Wayne
State University) [70, 71]. Parameters therein are based on
extinction coefficients of nearest neighbors in RNA [72].
RNA Oligonucleotide Synthesis.
The oligonucleotides RI and R4 and the two oligonucle-
otides that comprise the duplex R2 were synthesized by run
off transcription of synthetic DNA templates using T7 RNA
polymerase [50]. Oligonucleotide R3 was purchased from
IDT (Coralville, Iowa). Purity of all oligonucleotides was
determined to be >90% from analytical kinase experiments
completed as previously described [51]. Plasmids encoding
the selected sequences were amplified via PCR with a
primer that contained a recognition site for T7 RNA poly-
merase. (See "Selection of RNA Internal Loops", infra, for
complete details.) The products of the PCR reaction were
then used directly for transcription using the same methods
described above. Reactions were purified on a denaturing
17% polyacrylamide gel. Products were visualized and
extracted from the gel as described in "General Methods",
supra.
Attachment of Aminoglycosides to N-Hydroxyl Succin-
imde-Activated Sepharose.
A 2.4 mL suspension of resin in isopropanol (1.2 mL of
resin, loading 18 µmol/mL) was placed into a BioRad
polyprep chromatography column and washed twice with 10
mL of H2O. To the washed resin was added 50 mg (105
µcool) of kanamycin A in 5 mL of Na2CO3 buffer, pH 9.0,
and the resin was tumbled overnight at 4° C. After incuba-
tion, the resin was washed 2x with 10 mL of buffer, and the
remaining succinimide esters were quenched with 5 mL of
10 mM ethanolamine in 5% Na2CO3 (1 h at room tempera-
ture ("RT") with tumbling) The resin was washed with water
and then sequentially washed with 10 mL of 10 mM
NH4OAc, pH 4.5, and 10 mL of 10 mM Tris.HCI, pH 8.0.
These steps were repeated 3x, and the resin was stored in 10
mM Tris.HCI, pH 8.0 at 4° C. Excess aminoglycoside
relative to succinimide esters loaded on the resin and incu-
bation at 4° C. were used for conjugation to allow reaction
to occur preferentially at the 6' amino position of kanamycin
A. Previous experiments have shown that this position is the
most reactive when aminoglycosides are conjugated to dyes
that contain succinimide esters and to resin [54, 60, 73].
Selection of RNA Internal Loops that Recognize
Kanamycin A.
Each of the oligonucleotides was refolded separately in
Hybridization Buffer ("HB") containing 8 mM Na2HPO31
pH 7.0, 1 mM EDTA, and 185 mM NaCl by heating for 5
min at 65° C. and then cooling to RT on the benchtop.
Oligonucleotides were then transferred to 4° C. and mixed
together. Before the oligonucleotides were hybridized with
the resin, 200 µg of BSA was added to the samples. Each
selection experiment was completed with 10 picomoles of
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5'-end labeled RI and 20-fold higher concentration of each
control oligonucleotide (R2-R4, Dl, D2) over the concen-
tration of RL
A 100 µL aliquot of resin slurry (10 µL of resin) was
5 placed into a 2.5 mL BioRad column and washed 3x with 1
mL of 4° C. HB. The resin was then washed as follows: (1)
2.5 mL of HB containing 10 pmoles of RI; (2) 5 mL of HB;
(3) 2.5 mL of HB containing 200 pmoles of all RNA chase
oligonucleotides (R2-R4); (4) 2.5 mL of HB containing 200
io pmoles of all DNA chase oligonucleotides (Dl, D2); (5) 2x5
mL of HB. At this stage, liquid scintillation counting was
used to ensure that only background radioactivity was being
eluted from the column. Bound RNAs were eluted by
delivering a 2 mL solution of HB containing 1 mM of the
15 immobilized ligand. Scintillation counting of the elution
showed that only a small percentage of RI (-4%) bound to
the immobilized ligand.
The eluate was concentrated to 500 µL with 2-butanol and
ethanol precipitated with 100 µg of glycogen as a carrier.
20 The sample was resuspended in 100 µL of H2O and treated
with RQ DNase I (RNase-free, Promega) by incubation at
37° C. for 3 h. An equal volume of stop buffer was added to
the reaction, and the sample was incubated at 65° C. for 10
min to inactivate the DNase. After phenol: chloroform
25 extraction and ethanol precipitation, the sample was used as
a template in RT-PCR reactions.
RT-PCR reactions were completed as described previ-
ously [34, 55, 74]. Control experiments were run to ensure
that there was no contamination in the samples, including no
30 template and template without RT controls. Primers used for
RT-PCR experiments are: PCR primer, 5' GGCCGAAT-
TCTAATACGACTCACTATAGGGAGAGGGTTTAAT
(SEQ ID NO: 1), containing a T7 promoter for transcription
with RNA polymerase; RT primer, 5' CCTTGCTCCAAT
35 (SEQ ID NO: 2). RT reactions were completed by annealing
20 µL of the isolated RNA solution and 2µL of a 100 µM
solution of RT primer at 70° C. for 10 min followed by
incubation on ice for 10 min. Then, 1.6 µL of 25 mM dNTPs,
0.8 µL of 10 mg/mL BSA, 4µL of I0xRT buffer (supplied
4o by the manufacturer), and 0.1 µL of RT or H2O for no RT
controls were added. The reaction was allowed to proceed
for 1 h at 60° C. at which point the reaction was quenched
by heating at 95° C. for 3 min. PCR amplification was
completed by adding 4µL of 100 µM PCR primer, 2µL of
45 100 µM RT primer, 0.6 µL of 250 mM MgC121 0.2 µL of Taq
polymerase, 13 µL of H2O, and 6µL of I0xPCR buffer.
Twenty cycles of PCR were completed at 95° C. for 1
min/72° C. for 1 min. Reactions were analyzed by running
an aliquot on a denaturing 17% polyacrylamide gel stained
50 with SYBR gold or ethidium bromide. Only experiments in
which the negative controls contained no product were
carried on towards cloning.
RT-PCR products were then digested with BamHI and
EcoRl and were ligated into a pUC19 vector that was
55 digested with the same enzymes [34, 55, 74]. The plasmids
were transformed into DHSa competent Escherichia coli
and plated on LB plates containing ampicillin, X-gal, and
IPTG. White colonies were used to inoculate 2.5 mL Luria
Bertani broth (LB) cultures containing ampicillin and were
60 grown overnight at 37° C. Plasmids were isolated from
bacteria using an Eppendorf fast plasmid mini kit. Sequenc-
ing reactions were completed by the Roswell Park Cancer
Institute's Biopolymer lab.
Microarray-Based Experiments.
65 Preparation of azide-functionalized glass slides. Aminosi-
lane slides (Sigma) were coated with ca. 2 mL of a 1%
melted agarose solution [31]. Slides were placed on the
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bench and allowed to dry to a clear film. The agarose-coated
slides were submerged in a 20 mM NaIO4 aqueous solution
for 30 min [31] followed by extensive washing in water
(300 min with frequent water changes). Slides were then
submerged in 10% aqueous ethylene glycol for 1.5 h and
were washed with water as described above. To display
azides, slides were reacted with 20 mM 3-azidopropylamine
in 0.1 M NaHCO3 overnight. The following morning, slides
were quenched by incubation for 3 min in NaCNBH3
solution (100 mg in 10 mL ethanol+40 mL PBS). Slides
were washed with water as described above and left to dry
to a clear film on the benchtop.
Click Reactions on the Slide Surface.
Click reaction conditions on the slide surface were opti-
mized using a FITC-neamine substrate by varying the con-
centrations of CuSO4, TBTA, and sodium ascorbate or
TCEP in Ix phosphate buffer containing 10% glycerol.
Solutions were incubated on the slide surface for 2 h at RT,
and then washed with 1 xSDS for 15 min and with water for
15 min. The slides were dried in a stream of air and imaged
using a Kodak Gel Imaging System equipped with a 535 mn
filter. The optimal reaction conditions found were 1 mM
CuSO4, 100 µM TBTA, and 5 mM sodium ascorbate.
Reactions are specific because no reaction occurs when Cu2+
or TBTA are removed from the reaction, and only slight
signal is observed in the absence of sodium ascorbate (FIG.
413). These conditions were used to immobilize 2.
Determination of IC50's and Relative Binding Amities.
In order to determine which concentration of 2 was
optimal for competitive binding assays, serially diluted 2
was applied to the chip surface and allowed to react for 2 h
at RT inside the microwell of a silicon gasket (GRACE
Biolabs, CWCS 50R-1.0, C-24780) (FIG. 5A). Each of the
wells was washed twice with water, and the slide was dried
in air. The 5' end 32P radiolabeled IL 7 was annealed in
1 xHB+40 µg/mL of BSA at 60° C. for 5 min and allowed to
slow cool on the benchtop for 10 min. It is important to note
that the hybridization buffer contains 1 mM EDTA, or 50
equivalents compared to the amount of Cu2+ used for the
click reaction. EDTA was included to ensure that Cu2+ does
not bind to the aminoglycoside and cleave the RNA phos-
phodiester backbone [75]. The annealed RNA oligonucle-
otide was hybridized with the chip surface for 30 min at RT.
Slides were washed twice for 2 min with 1 xHB+40 µg of
BSA. Slides were dried in a stream of air and imaged using
a BioRad FX Imager. This direct binding measurement
showed that delivering 400 nL of a 2.5 mM solution of 2 to
the array was sufficient to observe binding to radiolabeled IL
7.
IC50's were determined by incubating serially diluted
competitor RNA and trace radiolabeled IL 7 in microwells
formed using a silicon gasket. Briefly, the internal loop for
which the IC51 was determined was annealed in 1 xHB+40
µg/mL BSA as described above. IL 7, which was used to
optimize the concentration of 2 in the spotting solution, was
annealed separately in the same manner. After slow cooling
on the benchtop for 10 min, the radiolabeled internal loop
was added to serially diluted competitor RNA, and the
sample applied to a microwell. The solution was allowed to
equilibrate with the surface for 30 min at RT after which the
slide was washed twice with 1xHB+40 µg/mL BSA. After
drying in a stream of air, the slides were exposed to a
phosphorimager plate and imaged using a Bio-Rad FX
Imager. The data were quantified using Bio-Rad's Quanti-
tyOne software, and the IC50's were determined using
SigmaPlot's four-parameter logistical curve fit.
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Enzymatic Probing of RNA. Hydrolysis and Nuclease TI
Ladders.
Hydrolysis ladders were generated by incubating 5' end
32P radiolabeled RNA oligonucleotides in 150 mM
5 NaHCO31 pH 10 and 1 mM EDTA for 4 min at 95° C.
Nuclease TI cleaves after single stranded guanosine nucleo-
tides. A TI Ladder was generated under denaturing condi-
tions by incubating radiolabeled RNA oligonucleotides in 20
mM sodium citrate, pH 5, 7 M urea, 1 mM EDTA, and 0.25
10 a of TI at 55° C. for 5 min. Both reactions were quenched
by adding equal volumes of stop buffer (IXTBE, 8 M urea,
and 1 mM EDTA).
RNase A and S1 Nuclease Mapping.
The binding site(s) of 2 was determined using a nuclease
15 protection assay. For RNase A mapping experiments, radio-
labeled oligonucleotide was annealed as described above.
After slow cooling, serially diluted concentrations of 2 were
added, and the resulting solution was allowed to equilibrate
for 30 min at RT. Approximately 6 µunits of RNase A were
20 added, and the reaction was allowed to proceed for 10 min.
The reaction was quenched by addition of an equal volume
of stop buffer, and the products were separated on a dena-
turing 17% polyacrylamide gel.
For S1 nuclease mapping experiments, the radiolabeled
25 oligonucleotide was annealed as described except the buffer
used was 50 mM sodium acetate (pH 4.5), 280 mM NaCl,
and 4.5 mM ZnSO4. The solution was allowed to equilibrate
for 30 min at RT after the addition of serially diluted
concentrations of 2, and then 10 units of S1 were added. The
30 reaction was quenched after 10 min at RT, and the products
were separated on a denaturing 17% polyacrylamide gel.
Example 4 A Small Molecule Microarray
Platform to Select RNA Internal Loop-Ligand
35 Interactions: Overview
In this Example 4 and in the following Examples 5-6, we
describe a microarray platform to complete nucleic acid
selections that combines the advantages of selection meth-
40 ods and small molecule microarrays. Our basic approach is
to immobilize ligands onto an agarose microarray surface
and screen the ligands for binding to an RNA motif library.
The RNAs that bind members of the ligand library are
harvested directly from the array surface by gel excision,
45 cloned, and identified via sequencing. This approach was
applied toward identifying the RNA internal loops that
bound 6'-N-5-hexynoate kanamycin A (21, FIG. 7). Results
show that 21 binds to internal loops that can form potential
CA pairs. All selected RNA internal loops bind 21 with Kd
50 values :522 nM.
Further details regarding the experiments described in this
Example 4 and in the following Examples 5-6 can be found
in Childs-Disney et al., "A Small Molecule Microarray
Platform to Select RNA Internal Loop-Ligand Interac-
55 tions.," ACS Chem. Biol., 2(11):745-754 (2007) and in the
associated Supporting Information (available on the internet
at http://pubs.acs.org/subscribe/journals/acbcct/suppinfo/
cb700l74r/cb700174r-File003.pdf), which are hereby incor-
porated by reference.
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Example 5 A Small Molecule Microarray
Platform to Select RNA Internal Loop-Ligand
Interactions: Results and Discussion
65 The Microarray Platform and the RNA Library.
Optimization of the merging of nucleic acid selections
and small molecule microarrays required a unique microar-
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ray surface that is robust enough for ligand screening and
allows bound RNAs to be harvested directly from the array
surface. We found that the optimal surface for this applica-
tion is an agarose-coated microarray [31-33]. Agarose pro-
vides a three-dimensional surface for high ligand loading 5
and a versatile surface to accommodate a variety of immo-
bilization chemistries, and bound RNAs can be harvested
from the array surface by simple excision of the agarose
from ligand-functionalized positions (FIG. 813).
The RNA library (22) that was screened for binding 21 io
has six randomized positions displayed in a 3x3 nucleotide
internal loop pattern (FIG. 9) (34). By focusing on selecting
RNAs from this library, we focus selections only on small
RNA motifs that are likely to be found as constituents of
larger RNAs. This is in contrast to SELEX, which uses 15
libraries with —15 randomized nucleotides. These 15-mers
are very difficult to find in biological RNAs; however, in rare
occasions SELEX has proven successful in RNA-targeting
endeavors [35, 36]. Library 22 has 4096 members that can
form a variety of internal loops and also base paired regions. 20
Specifically, 2 contains 1600 different 3x3 internal loops,
1200 different 2x2 loops, 1080 different 1xI loops, and 216
different base paired regions. (These values were calculated
by assuming that a GU pair is a standard RNA pair and that
two 1x1 internal loops cannot be separated by a base pair; 25
these structures are counted as 3x3 loops.)
Development of the Microarray Selection Method.
An array containing 50 ligand-functionalized spots was
constructed by immobilizing 21 onto azide-functionalized
surfaces via a Huisgen dipolar cycloaddition reaction [37, 30
38]. The array was then probed for binding to 5' end
32
P-labeled 22. All positions where 21 was immobilized
bound members of 22 with similar intensities (FIG. 813). A
diagonal of spots was excised from the array to assess if
bound RNAs can be harvested precisely without affecting 35
adjacent spots. Images of the array taken before and after
excision show that RNA was harvested only from the
desired positions and that signals in the surrounding spots
were unaffected (FIG. 813); thus there is no cross-contami-
nation between spots. Harvested RNA is suitable for ampli- 40
fication by reverse transcriptase polymerase chain reaction
(RT-PCR), cloning, and sequencing to identify the selected
library members (FIG. 10A). Next, we immobilized serially
diluted concentrations of 21 onto azide-agarose and incu-
bated the slide with 5' end 32P-labeled 22 and unlabeled 45
chase oligonucleotides (FIG. 9). Chase oligonucleotides
included a mimic of the stem (23) and hairpin (24) in 22 and
DNAs that formed d(GC) (25) and d(AT) (26) Watson-Crick
pairs. This combination was used to ensure that only internal
loop-small molecule interactions were probed in the selec- 50
tion and that interactions were RNA-specific. For the experi-
ments in FIGS. 10A-10C, chase oligonucleotides were
added in 1000-fold excess over 22 and in excess over the
amount of ligand delivered to the array surface. Under these
conditions, concentration-dependent binding is observed to 55
22 with signals that are well above background (FIGS.
10A-10B). Six samples were collected from the surface
where different amounts of 21 were immobilized (FIG. 10A)
and amplified by RT-PCR (FIG. 10C). RT-PCR product was
only observed when samples were taken from positions 60
functionalized with 21 and when RT was added to the
RT-PCR reactions. No RT-PCR product was observed when
samples were taken from a position where 21 was not
delivered or when RT was not added to the RT-PCR reaction,
provided :530 cycles of PCR were used. 65
One advantage of screening different concentrations or
loadings of ligands is higher amity RNA motif-ligand
OW
interactions should be identified at lower ligand loadings. To
determine if this is indeed the case, we studied the binding
of the pools of RNAs harvested from 1+ (higher ligand
loading) and 2+ (lower ligand loading) by using a fluores-
cence-based assay. Compound 21 was fluorescently labeled
(21-FL, FIG. 7) by reacting Boc-protected 21 with propar-
gylamine using the Huisgen dipolar cycloaddition reaction
used to anchor 21 onto the array surface. The product of this
reaction was reacted with fluorescein isothiocyanate to yield
21-FL. Dissociation constants for the binding of 21-FL to
the library of RNAs was determined because the fluores-
cence emission of 21-FL decreased as a function of RNA
concentration. The resulting curves were used to determine
dissociation constants. Results show that Kd values for 1+
and 2+ are 65 nM and 11 nM, respectively (FIG. 10C).
Evidently, RNAs harvested at a lower ligand loading have
higher aflinities for 21.
Since RNAs harvested from the surface can be RT-PCR
amplified and subsequently used as templates for runoff
transcription, multiple rounds of selection can be completed
if desired. The ability to complete selections at different
ligand loadings on the same surface demonstrates that this
platform can be used to complete multiple selections in
parallel on a single array.
To further illustrate that multiple selections can be com-
pleted on a single agarose array platform, we immobilized a
four-member azido-aminoglycoside library (FIG. llC,
28-31) onto alkyne-functionalized agarose [37, 39] and
selected members of 22 that they bound. Each library
member was immobilized at five different loadings and
probed for binding 22 in the presence of 23-26. Members of
22 bound to these structures with signals that depend on both
the aminoglycoside loading and identity. Bound RNAs at the
indicated positions in FIG. 11A were harvested and were
cleanly RT-PCR amplified over positions excised from
where aminoglycoside was not delivered to the array surface
(background) (N.C., FIG. 11B). When only the number of
aminoglycosides are considered for binding 22, 4x4096 or
16,382, interactions were probed in duplicate; however if the
number of aminoglycosides (four) and their loadings (five
each) are considered, 4x5x4096, or 81,920, interactions
were probed in duplicate.
Analysis of the Sequences of the Selected Structures that
Bind 21.
Selected higher amity RNAs from 2+ (FIG. 10C) were
cloned and sequenced, and their secondary structures pre-
dicted by free energy minimization using the RNASTRUC-
TURE program (FIG. 12) [8]. Interestingly, many of the
selected loops share sequence similarities. There is a clear
preference for loops with adenine across from cytosine. (We
state adenine across from a cytosine rather than A-C pair to
denote that we do not know if these bases are indeed paired.)
Of the 16 loops identified from the selection, (62.5%)
contain at least one adenine across from a cytosine, in
contrast to only 33% of all library members (two-tailed
p-value-0.0124). For each internal loop class, the selection
of at least one adenine across from an cytosine is above the
rate if the selection were random: 60% of 1x1 nucleotide
internal loops, 66% of 2x2 nucleotide internal loops, and
60% of 3x3 nucleotide internal loops. (Of the 1080 1x1
nucleotide internal loops in 22, 20% have an adenosine
across from a cytosine; 36% of 2x2 nucleotide internal loops
contain at least one adenosine across from a cytosine; 44%
of 3x3 nucleotide internal loops contain at least one adenos-
ine across from a cytosine. For the entire library, 22, 33% of
the loops contain at least one adenosine across from a
cytosine.
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Other sequence preferences are also observed. For the 2x2
nucleotide loops, the predicted lowest free energy structures
show preferences for pyrimidines neighbored by adenine
across from cytosine (two-tailed p-value-0.0093). The pref-
erence for pyrimidines in 2x2 nucleotide internal loops was 5
also observed in our resin-based selection, as described in
Examples 1-3, supra. Interestingly, many of the 1x1 and 2x2
nucleotide internal loops are closed by G•U base pairs. The
predicted lowest free energy structures of the 30 nucleotide
loops also show a preference for purines (two-tailed io
p-value-0.0309). In fact, for the two 2x2 and two 30
nucleotide internal loops that do not contain an adenine
across from a cytosine, three of them contain either a
guanine across from a guanine or a cytosine across from a
cytosine, which are both observed in the 1x1 loops. This 15
may suggest that the motifs displayed in the 1 x I nucleotide
loops are also displayed in the 30 nucleotide loops. The one
2x2 nucleotide loop that does fit either criterion (IL 28) has
tandem guanines across from adenines, which are displayed
in many of the selected 3x3 nucleotide loops (IL 32, IL 33, 20
and IL 35). The exact pairings that give rise to these
structural features will have to be determined through struc-
tural biology investigations, but it will be interesting to see
if these sequences display a similar RNA structural scaffold
to bind 21. 25
Measuring the Aflinities of Selected Structures to 21-FL.
The aflinity of each loop was determined using the
fluorescence assay described above. Each selected internal
loop binds to 21 with a similar aflinity, all with Kd values
:522 nM (FIG. 12). The range of dissociation constants (5-22 30
nM) corresponds well to the dissociation constant deter-
mined for the pool of RNAs harvested from position 2+ (11
nM). In contrast, 21-FL binds more weakly to the chase
oligonucleotides and the library. The fluorescence intensity
of 21-FL did not change in the presence of 23, 24, and 25+26 35
at concentrations up to 5µM (FIG. 813). The aflinity for 22
(the entire library) was 280 nM while the aflinity for the
empty cassette, 27, was 1.3 µM. Interactions between 21-FL
and 27 likely occur between the deoxystreptamine ring and
G•U pairs in the stem, which have been reported as amino- 40
glycoside interacting motifs in other RNAs that bind amino-
glycosides [41]. tRNAphe has also been shown to bind
aminoglycosides [42] and binds 21-FL with a Kd of 700 nM.
The dissociation constants for the two highest affinity
loops from our resin-based selection were also determined 45
using the fluorescence-based assay. (We state adenine across
from a cytosine rather than A-C pair to denote that we do not
know if these bases are indeed paired.) Both loops,
50
5'UUU3' and 5 1 ACU3'
3'UCA5' 3 1 UUU5'
bind as tightly to 21-FL as the highest affinity 2x2 loop from
the microarray selection with dissociation constants of 5±0.4 55
and 4±0.9 nM, respectively.
The affinities of the 1x1 nucleotide loops for 21-FL have
a range of 5-12 nM (FIG. 12), and GG, AC, and CC loops
are represented. It should be noted that previous experiments
have also found that several aminoglycosides bind a 1 x  CC 60
internal loop that is derived from the untranslated region in
thymidylate synthase mRNA [43, 44]. In these previous
reports, the dissociation constants for kanamycin B and
tobramycin were 1.1 and 0.87 µM, respectively, in a buffer
containing 1 mM MgCl2 and CaC121 150 mM NaCl, 5 mM 65
KCl, and 20 mM HEPES (pH 7.5) [44]. We studied the
binding of 21-FL to IL 24 in the same buffer and observed
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a similar aflinity (Kd of 0.21 ±0.04 µM) despite differences in
closing base pairs and aminoglycoside structure. The differ-
ence in binding affinity between the two buffers is due to the
presence of divalent metal ions and increased pH, which are
well known to decrease the affinity of aminoglycosides to
RNA [17].
Because deoxystreptamine binds G•U pairs, the stem in
22 was mutated to assess if loop non-nearest neighbors
contribute to binding affinity (FIG. 13). All G•U pairs and
most AU pairs were mutated to GC. The loop closing base
pairs (both AU pairs) were not mutated because previous
reports have shown that closing base pairs can affect internal
loop structure [45, 46]. Results from fluorescence experi-
ments show that similar Kd values are observed when the
loops are displayed in either cassette (FIG. 13). Evidently,
cassette nucleotides are not important for recognition of the
selected loops by 21-FL.
To determine if selected loops have aminoglycoside pref-
erences, the binding of five aminoglycosides, 21, kanamycin
A, kanamycin B, tobramycin, and neamine (FIG. 7) to the
pool of RNAs from spot 2+ (FIG. 10C) was probed using a
competitive binding assay [43]. The Kd values determined
for 21, kanamycin A, and kanamycin B were 12 nM, 9 nM,
and 12 nM, respectively. The pool bound approximately
9-fold more weakly to tobramycin (Kd 85 nM), consistent
with the 3' hydroxyl group in ring I contributing to binding
to the library of structures. Binding to neamine was even
weaker as there was no change in fluorescence up to 500 nM
neamine. We also tested a single RNA sequence identified to
bind 21, IL 34, in the same manner. These experiments
mirror the results of the pool of RNAs isolated from 2+,
showing that 21, kanamycin A, and kanamycin B bind to IL
34 with Kd values of 7 nM, 5 nM, and 5 nM, respectively.
Binding to neamine and tobramycin was also much weaker.
Both sets of experiments suggest that the recognition of 21
and related aminoglycosides (kanamycins A and B) is not
due to simple charge-charge interactions; rather, there are
specific interactions between the functional groups dis-
played by the aminoglycosides and the RNA. The weaker
affinities for tobramycin and neamine suggest that both the
3' hydroxyl groups in ring I and ring III are important for
binding. Interestingly, in both cases, 21 and 21-FL bind with
the same affinity, showing that the fluorescence tag, the
triazole, and the 6' NH2 groups do not contribute signifi-
cantly to binding. It is not surprising that the 6' NH2 is not
important for binding since structures were selected that
bind a 6' acylated derivative of kanamycin A. It should be
noted, however, that the 6' NH2 forms important stabilizing
contacts for aminoglycoside recognition of the bacterial
rRNA A-site. When the 6' NH2 is acetylated by AAC(6')
resistance enzymes, binding to an oligonucleotide mimic of
the bacterial rRNAA-site is reduced 1000-fold [47]. There-
fore, there are differences in the molecular recognition of 21
to IL 34 and kanamycin A to the bacterial rRNA A-site.
Advantages of the Microarray Selection Platform.
The microarray selection platform is believed to have
several advantages over other selection methods. One is the
manner in which selected RNAs are harvested. In typical
resin-based selections, selected RNAs are eluted with a high
concentration of immobilized ligand which can introduce
potential kinetic biases. Since the highest affinity RNAs are
the most difficult to compete off, standard selection experi-
ments can inadvertently miss the best binders. Capillary
electrophoresis ("CE") SELEX has been developed to miti-
gate this problem [48]. The microarray method described in
this Example harvests bound RNAs by simple excision of
the agarose and gel extraction (FIG. 813), thus avoiding
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potential kinetic biases. RNAs can be harvested precisely
from the microarray surface; adjacent spots are unaffected
and the RNAs are free from cross-contamination (FIG. 813).
Therefore, the RNA is suitable for downstream applications
such as RT-PCR amplification and cloning, transcription of
RT-PCR products, multiple rounds of selection, and deter-
mination of dissociation constants. Another important
advantage of completing selections on a microarray platform
is the ability to determine dose response on a single array
(FIGS. 10A-10C). Standard selection methods only screen a
library of targets against one compound at a single loading.
Therefore, a separate experiment for each ligand loading is
required to construct a dose response. In this study, higher
amity interactions were identified at a lower ligand loading
(FIG. 10A). This result and the ones shown in FIGS.
11A-11B demonstrate that multiple selections can be com-
pleted on a single array surface. The number of parallel
screens is limited by the number of compounds that can be
placed onto an array surface from which bound RNAs can
be subsequently isolated. With manual methods, the mini-
mum number of compounds that can be screened is 50. It is
likely that robotic arraying of compounds and using auto-
mated spot pickers to harvest bound RNAs could increase
this number to at least hundreds of compounds. Finally, the
microarray method requires a reduced amount of ligand
compared to resin-based selections. Selected RNAs were
amplified from positions where as little as 250 pmol of
ligand were delivered to the array surface (FIGS. 10A and
10C, spot 2).
As discussed in Example 2 and elsewhere hereinabove,
our long-range goal is to develop a database of RNA-ligand
partners to facilitate the rational design of small molecules
that target RNA. Clearly, new methods need to be developed
because of the diverse number of RNA secondary structures
and ligands that must be screened to construct such a
database. Therefore, we developed a small molecule carbo-
hydrate microarray platform to identify RNA-ligand inter-
actions in which multiple selections and dose response can
be completed in a single experiment. Traditional ligand
discovery efforts screen a validated RNA drug target against
a ligand library. This type of screen, however, gives little
insight into potential off-target effects. Our microarray plat-
form screens a library of RNAs to determine the RNA
motifs) preferred by a ligand. These preferences can then be
used in RNA targeting applications while identifying poten-
tial bystander RNAs.
Once a wide variety of RNA motif ligand interactions
have been identified, methods for modular assembly of
ligands can be developed, such as those applied for poly-
amide recognition of Watson-Crick paired DNA [49].
Microarray-based screening is well suited for identifying
ligands that will be used for modular assembly because
chemistries used to anchor compounds onto surfaces can be
used to link ligand modules together.
Example 6 A Small Molecule Microarray
Platform to Select RNA Internal Loop-Ligand
Interactions: Materials and Methods
This Example 6 describes the materials and methods that
were used in carrying out the experiments described in
Example 5.
General Methods.
Chemicals were purchased from Sigma Aldrich, except
radioactivity which was purchased from Perkin-Elmer.
Chase RNA oligonucleotides were purchased from Dharma-
con and were deprotected using the manufacturer's standard
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protocol. The chase DNA oligonucleotides (25 and 26, FIG.
3) and all DNA templates were purchased from IDT (Cor-
alville, Iowa). The RNA 3x3 nucleotide internal loop library
was transcribed from a DNA template using T7 RNA
5 polymerase from a Strategene RiboMaxxx transcription kit
[50]. Oligonucleotides were radioactively labeled on their 5'
ends and purified as described in [51]. All solutions were
made with DEPC-treated water.
Microarray Construction, Hybridization, and Harvesting
io Bound RNAs from the Agarose Functionalized Array.
The 6'-N-5-hexynoate kanamycin A ligand (21) was spot-
ted in 10 mM sodium phosphate, pH 7.5, 1 mM TCEP, 1 mM
CuSO4, 100 µM TBTA ligand [37], and 10% glycerol onto
azide-displaying agarose slides [31] constructed as
15 described in [40]. Azidoaminoglycoside (28-31) were
immobilized onto alkyne-functionalized agarose surfaces as
described in [52]. The alkyne-functionalized arrays were
constructed as described hereinabove in Examples 1-3
except that propargylamine was used instead of 3-azidopro-
20 pylamine. A grid affixed to the back of the microarray was
used as a guide for spatial arraying. After immobilization,
the grid was removed, and the slides were incubated over-
night in a humidity chamber. The following morning, they
were washed by submersion in 30 mL of hybridization
25 buffer ("HB") (8 mM Na2HPO41 pH 7.0, 185 mM NaCl, and
1 mM EDTA) and then rinsed with water.
Microarrays were hybridized with a solution containing 5'
end 32P-labeled RNA 30 nucleotide library (22) and chase
oligonucleotides (FIG. 9). Chase oligonucleotides were used
30 to ensure that RNA internal loop ligand interactions were
probed. Each oligonucleotide (2 pmol of 5' end 32P-labeled
RNA 3x3 internal loop library (22), 2 nmol of each chase
oligonucleotide for experiments with 21 and 12 pmol of
internally labeled 22 (a 32P-ATP, transcription with Strata-
35 gene RNAMaxx kit using half of the suggested cold ATP and
4 µL of 32P-ATP or 40 µCi) and 20 nmol of each chase
oligonucleotide for experiments with 28-31) was annealed
separately in FIB by heating at 95° C. for 1 min and cooling
to RT on the benchtop. After cooling to RT, the solutions
40 containing each oligonucleotide were mixed together and 40
µg/mL BSA was added in a total volume of 400 µL.
Prior to hybridization, arrays were pre-equilibrated with
400 µL of hybridization buffer containing 40 µg/mL of BSA
for 5 min. The buffer was distributed evenly across the array
45 surface using a custom-cut piece of PARAFILMTM that was
placed over the applied solution. The PARAFILMTM and
buffer were then removed. The solution containing 22 and
chase oligonucleotides was applied to the array surface and
distributed evenly as described. Slides were hybridized for
5o approximately 30 min at RT. After incubation, the PARA-
FILMTM was removed from the slide, and the slide was
submerged in 30 mL of hybridization buffer for 3 min with
gentle agitation. The buffer was replaced, and the step was
repeated. The residual buffer was removed from the array
55 surface by applying a gentle stream of air, and the chip was
allowed to remain at RT for 30 min to dry completely. The
array was exposed to a phosphorimager plate that was
scanned on a BioRad FX phosphorimager (FIG. 813).
An autoradiogram of the array and a grid used to spot 21
60 were placed under the microarray as a template to excise the
agarose at positions that captured RNA. A 200 mL aliquot of
hybridization buffer was added to each position. After 30 s,
excess buffer not absorbed by the surface was removed. The
gel slice at that position was then excised using a toothpick,
65 and the gel slice was placed into thin-walled PCR tubes with
18 µL of H2O, 2µL of IOxDNase I buffer, and 2 units of
RNase-free DNase I (Promega). The tubes were vortexed
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and spun at 8000 g for 4 min to force the agarose to the
bottom of the tube. The solution was incubated at 37° C. for
2 h, and the reaction was quenched by addition of 2µL of
I OxDNase stop solution. The sample was then incubated at
65° C. for 10 min to inactivate completely the DNase.
Aliquots of this sample were RT-PCR amplified. We found
that spot 2 (250 µcool of 21 delivered to the surface) was the
lowest amount of ligand from which captured RNA can be
amplified over the background (spot 3+) (FIGS. 10A and
10C). RT-PCR product was observed after 25 cycles of PCR
following the RT step. Attempts were made to amplify
positions where lower amounts of 21 were delivered, but
they required >35 cycles for amplification. Under these
conditions, RT-PCR product was observed from positions
where 21 was not delivered. We therefore only processed the
2+ position.
RNA Internal Loop Ligand Interaction Affinity Measure-
ments.
Direct Binding Assay Measurements. A fluorescence-
based assay was used to determine binding affinities by
monitoring the change in fluorescence intensity of 21-FL
(FIG. 7) as a function of RNA concentration (up to 300 nM
for selected loops; there is a nonspecific binding mode at
concentrations >300 nM). RNA was annealed in 1 xHB+40
µg/mL BSA at 60° C. for 5 min and allowed to slow cool on
the benchtop. Then, 21-FL in 1xHB+40 µg/mL BSA was
added to the solution of RNA to a final concentration of 10
nM, and the RNA serially diluted into 1 xHB+40 µg/mL
BSA+10 nM 21-FL. Samples were then placed into a well
of a black 96-well plate and allowed to equilibrate for at
least 30 min before reading fluorescence intensity on a
Bio-Tek Synergy HT fluorescence plate reader (excitation,
485 mu; emission, 528; sensitivity, 70). Several different
times were sampled to ensure that the fluorescence intensity
was taken after these interactions reached equilibrium. A
decrease in fluorescence intensity was observed as a func-
tion of RNA concentration. The binding measurements for
each oligonucleotide were completed in at least triplicate.
Dissociation constants were determined by curve fitting, and
reported values are the mean of at least three experiments.
The data were fit to:
I = to + 0.500.50x{] [21- FL). + [RNA). + Kr) -
(([21 - FL). + [RNA] + Kr)2 - 4[21 - FL]. [RNA]o)0s)
where I is the observed fluorescence intensity, I, is the
fluorescence intensity in the absence of RNA, AE is the
difference between the fluorescence intensity in the absence
of RNA and in the presence of infinite RNA concentration,
[21-FL], is the concentration of 21-FL, [RNA], is the
concentration of the selected internal loop or control RNA,
and Kt is the dissociation constant. We also plotted the
change in fluorescence as a function of RNA equivalents for
all selected internal loops. Saturation is observed between
0.8 and 1.3 equiv, suggesting a 1:1 stoichiometry. Control
experiments were completed to ensure that fluorescein (the
fluorescent tag) was not contributing to binding by incubat-
ing serial dilutions of IL 24 up to 3µM with 10 nM
FITC-triazole and 10 nM fluorescein.
Competition Binding Experiments.
A solution containing 75 nM IL 34 was refolded in 1 x
hybridization buffer+40 µg/mL BSA at 60° C. for 5 min.
After slow cooling on the benchtop, 21-FL was added to a
final concentration of 10 nM. The competing, unlabeled
28
aminoglycoside was then added, and the resulting solution
was serially diluted into 1 x hybridization buffer+40 µg/mL
BSA+10 nM 21-FL containing 75 nM IL 34. The solutions
were equilibrated for 30 min at RT, and the fluorescence
5 intensities were measured on a Bio-Tek HT fluorescence
plate reader. Data were fit to:
6-(1/(2 [2 1 -FL]))(K,+(K1Kd) [C ]+[RNA]+[21-FL]-
((K,+(K,/Kd) [C ]+[RNA]+[21-FL])2-4[21-FL]
10 [RNA])0.5)+A
where O is the fraction of 21-FL bound, Kt is the dissociation
constant determined for IL 34 from direct binding assays, Kd
is the dissociation constant of the competing, unlabeled
15 aminoglycoside, [Ct] is the concentration of competing
aminoglycoside, and [RNA] is the concentration of IL 34.
Although the invention has been described in detail for
the purpose of illustration, it is understood that such detail
is solely for that purpose, and variations can be made therein
20 by those skilled in the art without departing from the spirit
and scope of the invention which is defined by the claims
that are set forth below after the section entitled "Refer-
ences".
25 REFERENCES
1. Doudna, J. A. (2000) Structural genomics of RNA, Nat.
Struct. Biol. 7 Suppl., 954-956.
2. Batey, R. T., et al. (1999) Tertiary motifs in RNA structure
30 and folding, Angew. Chem., Int. Ed. Engl. 38, 2326-2343.
3. Zaug, A. 7., et al. (1986) The intervening sequence RNA
of tetrahymena is an enzyme, Science 231, 470-475.
4. Lagos-Quintana, M., et al. (2001) Identification of novel
genes coding for small expressed RNAs, Science 294,
35 853-858.
5. Winkler, W., et al. (2002) Thiamine derivatives bind
messenger RNAs directly to regulate bacterial gene
expression, Nature 419, 952-956.
6. Gallego, 7., et al. (2001) Targeting RNA with small
40 molecule drugs: therapeutic promise and chemical chal-
lenges, Acc. Chem. Res. 34, 836-843.
7. Hamy, F., et al. (1997) An inhibitor of the Tat/TAR RNA
interaction that effectively suppresses HIV-1 replication,
Proc. Natl. Acad. Sci. U.S.A. 94, 3548-3553.
45 8. Mathews, D. H., et al. (2004) Incorporating chemical
modification constraints into a dynamic programming
algorithm for prediction of RNA secondary structure,
Proc. Natl. Acad. Sci. U.S.A. 101, 7287-7292.
9. Mathews, D. H., et al. (1999) Expanded sequence depen-
50 dence of thermodynamic parameters improves prediction
of RNA secondary structure, J. Mol. Biol. 288, 911-940.
10. Woese, C. R., et al. (1980) Secondary structure model for
bacterial 16S ribosomal RNA: phylogenetic, enzymatic
and chemical evidence, Nucleic Acids Res. 8, 2275-2293.
55 11. Fourmy, D., et al. (1996) Structure of the A site of
Escherichia coli 16S ribosomal RNA complexed with an
aminoglycoside antibiotic, Science 274, 1367-1371.
12. Lynch, S. R., et al. (2003) Comparison of X-ray crystal
structure of the 30S subunit-antibiotic complex with
60 NMR structure of decoding site oligonucleotide-paromo-
mycin complex, Structure (Cambridge, Mass., US) 11,
43-53.
13. Carter, A. P., et al. (2000) Functional insights from the
structure of the 30S ribosomal subunit and its interactions
65 with antibiotics, Nature 407, 340-348.
14. Kaul, M., et al. (2006) Aminoglycoside induced reduc-
tion in nucleotide mobility at the ribosomal RNA a-site as
US 9,719,191 B2
29
a potentially key determinant of antibacterial activity, J.
Am. Chem. Soc. 128, 1261-1271.
15. Kaul, M., et al. (2004) Fluorescence based approach for
detecting and characterizing antibiotic-induced confor-
mational changes in ribosomal RNA: comparing amino-
glycoside binding to prokaryotic and eukaryotic ribo-
somal RNA sequences, J. Am. Chem. Soc. 126, 3447-
3453.
16. Shandrick, S., et al. (2004) Monitoring molecular rec-
ognition of the ribosomal decoding site, Angew. Chem.,
Int. Ed. Engl. 43, 3177-3182.
17. Thomas, J. R., et al. (2006) Biochemical and thermo-
dynamic characterization of compounds that bind to RNA
hairpin loops: toward an understanding of selectivity,
Biochemistry 45, 10928-10938.
18. Thomas, J. R., et al. (2005) Size-specific ligands for
RNA hairpin loops, J. Am. Chem. Soc. 127,12434-12435.
19. Thomas, J. R., et al. (2005) The relationship between
aminoglycosides' RNA binding proclivity and their anti-
plasmid effect on an IncB plasmid combating drug-
resistant bacteria: small molecule mimics of plasmid
incompatibility as antiplasmid compounds, Biochemistry
44, 6800-6808.
20. Denap, J. C., et al. (2004) Combating drug-resistant
bacteria: small molecule mimics of plasmid incompatibil-
ity as antiplasmid compounds, J. Am. Chem. Soc. 126,
15402-15404.
21. Klug, S. J., et al. (1994) All you wanted to know about
SELEX, Mol. Biol. Rep. 20, 97-107.
22. Joyce, G. F. (1994) In vitro evolution of nucleic acids,
Curr. Opin. Struct. Biol. 4, 331-336.
23. Griffey, R. IT., et al. (1999) Determinants of aminogly-
coside-binding specificity for rRNA by using mass spec-
trometry, Proc. Natl. Acad. Sci. U.S.A. 96, 10129-10133.
24. Swayze, E. E., et al. (2002) SAR by MS: a ligand based
technique for drug lead discovery against structured RNA
targets, J. Med. Chem. 45, 3816-3819.
25. He, Y., et al. (2004) Synthesis and evaluation of novel
bacterial rRNA-binding benzimidazoles by mass spec-
trometry, Bioorg. Med. Chem. Lett. 14, 695-699.
26. Seth, P. P., et al. (2005) SAR by MS: discovery of a new
class of RNA-binding small molecules for the hepatitis C
virus: internal ribosome entry site IIA subdomain, J. Med.
Chem. 48, 7099-7102.
27. Johnson, E. C., et al. (2003) Application of NMR
SHAPES screening to an RNA target, J. Am. Chem. Soc.
125, 15724-15725.
28. MacBeath, G., et al. (1999) Printing small molecules as
microarrays and detecting protein-ligand interactions en
masse, J. Am. Chem. Soc. 121, 7967-7968.
29. Disney, M. D., et al. (2004) Aminoglycoside microarrays
to explore interactions of antibiotics with RNAs and
proteins, Chemistry 10, 3308-3314.
30. Ratner, D. M., et al. (2004) Tools for glycomics: map-
ping interactions of carbohydrates in biological systems,
ChemBioChem 5, 1375-1383.
31. Afanassiev, V., et al. (2000) Preparation of DNA and
protein micro arrays on glass slides coated with an
agarose film, Nucleic Acids Res. 28, E66.
32. Dufva, M., et al. (2004) Characterization of an inexpen-
sive, nontoxic, and highly sensitive microarray substrate,
Biotechniques 37, 286-292294, 296.
33. Barrett, O. J., et al. (2006) Chemical microarrays to
identify ligands that bind pathogenic cells, ChemBio-
Chem 7, 1882-1885.
30
34. Bevilacqua, J. M., et al. (1998) Thermodynamic analysis
of an RNA combinatorial library contained in a short
hairpin, Biochemistry 37, 15877-15884.
35. Lato, S. M., et al. (1996) Screening chemical libraries for
5 nucleic-acid-binding drugs by in vitro selection: a test
case with lividomycin, Mol. Diversity. 2, 103-110.
36. Carlson, C. B., et al. (2003) Preferred RNA binding sites
for a threading intercalator revealed by in vitro evolution,
Chem. Biol. 10, 663-672.
io 37. Chan, T. R., et al. (2004) Polytriazoles as copper(I)-
stabilizing ligands in catalysis, Org. Lett. 6, 2853-2855.
38. Kolb, H. C., et al. (2003) The growing impact of click
chemistry on drug discovery, Drug Discovery Today 8,
1128-1137.
15 39. Kolb, H. C., et al. (2001) Click Chemistry: Diverse
Chemical Function from a Few Good Reactions, Angew.
Chem., Int. Ed. Engl. 40, 2004-2021.
40. Disney, M. D., et al. (2007) Using Selection to Identify
and Chemical Microarray to Study the RNA Internal
20 Loops Recognized by 6=-N-Acylated Kanamycin A,
ChemBioChem 8, 649-656.
41. Yoshizawa, S., et al. (2002) Sequence-specific recogni-
tion of the major groove of RNA by deoxystreptamine,
Biochemistry 41, 6263-6270.
25 42. Kirk, S. R., et al. (1999) tRNA(Phe) binds aminoglyco-
side antibiotics, Bioorg. Med. Chem. 7, 1979-1991.
43. Cho, J., et al. (2000) Specific binding of Hoechst 33258
to site 1 thymidylate synthase mRNA aminoglycoside
antibiotics are able to specifically bind the 5=-untrans-
30 lated region of thymidylate synthase messenger RNA,
Nucleic Acids Res. 28, 2158-2163.
44. Harada, K., et al. (1999) Screening RNA-binding librar-
ies using a bacterial transcription antitermination assay,
Methods Mol. Biol. 118, 177-187.
35 45. Wu, M., et al. (1996) Solution structure of (rGCG-
GACGC) 2 by two-dimensional NMR and the iterative
relaxation matrix approach, Biochemistry 35, 9677-9689.
46. SantaLucia, J., Jr., et al. (1993) Structure of (rGGC-
GAGCC) 2 in solution from NMR and restrained molecu-
40 lar dynamics, Biochemistry 32, 12612-12623.
47. Llano-Sotelo, B., et al. (2002) Aminoglycosides modi-
fied by resistance enzymes display diminished binding to
the bacterial ribosomal aminoacyl-tRNA site, Chem. Biol.
9, 455-463.
45 48. Mendonsa, S. D., et al. (2004) In vitro evolution of
functional DNA using capillary electrophoresis, J. Am.
Chem. Soc. 126,20-21.
49. Dervan, P. B. (2001) Molecular recognition of DNA by
small molecules, Bioorg. Med. Chem. 9, 2215-2235.
50 50. Milligan, J. F., et al. (1989) Synthesis of small RNAs
using T7 RNA polymerase, Methods Enzymol. 180,
51-62.
51. Disney, M. D., et al. (2000) Targeting a Pneumocystis
carinii group I intron with methylphosphonate oligo-
55 nucleotides: backbone charge is not required for binding
or reactivity, Biochemistry 39, 6991-7000.
52. Disney, M. D., et al. (2007) An aminoglycoside microar-
ray platform for directly monitoring and studying antibi-
otic resistance, Biochemistry 40, 11223-11230.
60 53. S. E. Osborne, A. D. Ellington, Chem. Rev. 1997, 97,
349117.
54. Y. Wang, R. R. Rando, Chem. Biol. 1995, 2, 281117.
55. Z. Shu, P. C. Bevilacqua, Biochemistry 1999, 38,
15369117.
65 56. V. P. Antao, S. Y Lai, I. Tinoco, Jr., Nucleic Acids Res.
1991, 19, 5901117.
57. G. Werstuck, M. R. Green, Science 1998, 282, 296117.
US 9,719,191 B2
31
58. M. I. Recht, D. Fourmy, S. C. Blanchard, K. D. Dahl-
quist, J. D. Puglisi, J. Mol. Biol. 1996, 262, 421ff.
59. G. MacBeath, S. L. Schreiber, Science 2000, 289,
1760ff.
60. M. D. Disney, S. Magnet, J. S. Blanchard, P. H. See- 5
berger, Angew. Chem. Int. Ed. Engl. 2004, 43, 15911f.
61. M. D. Disney, P. H. Seeberger, Chem. Biol. 2004, 11,
1701ff.
62. J. Roestamadji, I. Grapsas, S. Mobashery, J. Am. Chem.
Soc. 1995, 117, 11060ff. to
63. A. Vincze, R. E. Henderson, J. J. McDonald, N. J.
Leonard, J. Am. Chem. Soc. 1973, 95, 2677ff.
64. C. Ehresmann, F. Baudin, M. Mougel, P. Romby, J. P.
Ebel, B. Ehresmann, Nucleic Acids Res. 1987, 15, 9109ff. 15
65. D. Moazed, H. F. Noller, Nature 1987, 327, 389ff.
66. C. H. Wong, M. Hendrix, E. S. Priestley, W. A. Green-
berg, Chem. Biol. 1998, 5, 397ff.
SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 52
<210> SEQ ID NO 1
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<400> SEQUENCE: 1
ggccgaattc taatacgact cactataggg agagggttta at
<210> SEQ ID NO 2
<211> LENGTH: 12
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer
<400> SEQUENCE: 2
ccttgctcca at
<210> SEQ ID NO 3
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA motif library
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (16)..(18)
<223> OTHER INFORMATION: "n" can be A, C, G, or U
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (29)..(31)
<223> OTHER INFORMATION: "n" can be A, C, G, or U
<400> SEQUENCE: 3
gggagagggu uuaaunnnua cgaaaguann nauuggaucc gcaagg
<210> SEQ ID NO 4
<211> LENGTH: 18
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: stem sequence
<400> SEQUENCE: 4
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-continued
gggagauuug ggaauuac
<210> SEQ ID NO 5
<211> LENGTH: 18
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: stem sequence
is
<400> SEQUENCE: 5
guaauuuccg gagcaagg 18
<210> SEQ ID NO 6
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: hairpin loop sequence
<400> SEQUENCE: 6
cgcgaaagcg 10
<210> SEQ ID NO 7
<211> LENGTH: 20
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: chase oligonucleotide
<400> SEQUENCE: 7
cgcgcgcgcg cgcgcgcgcg 20
<210> SEQ ID NO 8
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: chase oligonucleotide
<400> SEQUENCE: 8
gcgcgcgcgc gcgcgcgcgc 20
<210> SEQ ID NO 9
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: chase oligonucleotide
<400> SEQUENCE: 9
atatatatat atatatatat 20
<210> SEQ ID NO 10
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: chase oligonucleotide
<400> SEQUENCE: 10
tatatatata tatatatata 20
<210> SEQ ID NO 11
<211> LENGTH: 40
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
M
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<220> FEATURE:
<223> OTHER INFORMATION: cassette sequence
<400> SEQUENCE: 11
gggagagggu uuaauuacga aaguaauugg auccgcaagg 40
<210> SEQ ID NO 12
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 12
gggagagggu uuaauuuuua cgaaaguaac uauuggaucc gcaagg 46
<210> SEQ ID NO 13
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA displaying an internal look motif
<400> SEQUENCE: 13
gggagagggu uuaauaucua cgaaaguauu uauuggaucc gcaagg 46
<210> SEQ ID NO 14
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 14
gggagagggu uuaaugauua cgaaagauua uauuggaucc gcaagg 46
<210> SEQ ID NO 15
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 15
gggagagggu uuaaucuaua cgaaaguacu aauuggaucc gcaagg 46
<210> SEQ ID NO 16
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 16
gggagagggu uuaauuccua cgaaaguaag uauuggaucc gcaagg 46
<210> SEQ ID NO 17
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 17
gggagagggu uuaaugauua cgaaaguaaa gauuggaucc gcaagg 46
36
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<210> SEQ ID NO 18
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 18
gggagagggu uuaaucggua cgaaaguacu uauuggaucc gcaagg 46
<210> SEQ ID NO 19
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 19
gggagagggu uuaauccuua cgaaaguaaa gauuggaucc gcaagg 46
<210> SEQ ID NO 20
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 20
gggagagggu uuaaucgcua cgaaaguaac aauuggaucc gcaagg 46
<210> SEQ ID NO 21
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 21
gggagagggu uuaaugaaua cgaaaguaau aauuggaucc gcaagg 46
<210> SEQ ID NO 22
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 22
gggagagggu uuaauuauua cgaaaguacu aauuggaucc gcaagg 46
<210> SEQ ID NO 23
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 23
gggagagggu uuaaucgcua cgaaaguagc uauuggaucc gcaagg 46
<210> SEQ ID NO 24
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
38
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<400> SEQUENCE: 24
gggagagggu uuaaugugua cgaaaguaug aauuggaucc gcaagg 46
<210> SEQ ID NO 25
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 25
gggagagggu uuaauccuua cgaaaguaga gauuggaucc gcaagg 46
<210> SEQ ID NO 26
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 26
gggagagggu uuaauauuua cgaaaguaaa gauuggaucc gcaagg 46
<210> SEQ ID NO 27
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 27
gggagagggu uuaauugaua cgaaaguacg aauuggaucc gcaagg 46
<210> SEQ ID NO 28
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 28
gggagagggu uuaaucuuua cgaaaguacc gauuggaucc gcaagg 46
<210> SEQ ID NO 29
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 29
gggagagggu uuaauuagua cgaaaguaga uauuggaucc gcaagg 46
<210> SEQ ID NO 30
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 30
gggagagggu uuaaucuuua cgaaaguaga aauuggaucc gcaagg 46
<210> SEQ ID NO 31
►ni
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<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 31
gggagagggu uuaauuagua cgaaaguagu gauuggaucc gcaagg 46
<210> SEQ ID NO 32
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 32
gggagagggu uuaaugaaua cgaaaguauc uauuggaucc gcaagg 46
<210> SEQ ID NO 33
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 33
gggagagggu uuaaucucua cgaaaguagg cauuggaucc gcaagg 46
<210> SEQ ID NO 34
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 34
gggagagggu uuaauuagua cgaaaguauc gauuggaucc gcaagg 46
<210> SEQ ID NO 35
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 35
gggagagggu uuaaucagua cgaaaguaug aauuggaucc gcaagg 46
<210> SEQ ID NO 36
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 36
gggagagggu uuaauuuaua cgaaaguacu aauuggaucc gcaagg 46
<210> SEQ ID NO 37
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 37
DA
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gggagagggu uuaaugaaua cgaaaguaug aauuggaucc gcaagg 46
<210> SEQ ID NO 38
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 38
gggagagggu uuaauuacua cgaaaguacc gauuggaucc gcaagg 46
<210> SEQ ID NO 39
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 39
gggagagggu uuaauccuua cgaaaguagc cauuggaucc gcaagg 46
<210> SEQ ID NO 40
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 40
gggagagggu uuaauuacua cgaaaguauc gauuggaucc gcaagg 46
<210> SEQ ID NO 41
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 41
gggagagggu uuaaugggua cgaaaguaga gauuggaucc gcaagg 46
<210> SEQ ID NO 42
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 42
gggagagggu uuaauaagua cgaaaguagc gauuggaucc gcaagg 46
<210> SEQ ID NO 43
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 43
gggagagggu uuaauagcua cgaaaguaau cauuggaucc gcaagg 46
<210> SEQ ID NO 44
<211> LENGTH: 46
<212> TYPE: RNA
►„
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<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 44
gggagagggu uuaauguaua cgaaaguagg gauuggaucc gcaagg 46
<210> SEQ ID NO 45
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA motif library
<400> SEQUENCE: 45
gggagagggu uuaauccuua cgaaaguaua aauuggaucc gcaagg 46
<210> SEQ ID NO 46
<211> LENGTH: 40
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: cassette sequence
<400> SEQUENCE: 46
gggagagggc cgccuuccga aaggaaggcg gcccgcaagg 40
<210> SEQ ID NO 47
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (16)..(18)
<223> OTHER INFORMATION: "n" can be A, C, G, or U
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (29)..(31)
<223> OTHER INFORMATION: "n" can be A, C, G, or U
<400> SEQUENCE: 47
gggagagggc cgccunnnuc cgaaaggann naggcggccc gcaagg 46
<210> SEQ ID NO 48
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 48
gggagagggc cgccuggguc cgaaaggaga gaggcggccc gcaagg 46
<210> SEQ ID NO 49
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 49
gggagagggc cgccuaaguc cgaaaggagc gaggcggccc gcaagg 46
<210> SEQ ID NO 50
<211> LENGTH: 46
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<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 50
gggagagggc cgccuagcuc cgaaaggaau caggcggccc gcaagg 46
<210> SEQ ID NO 51
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 51
gggagagggc cgccuguauc cgaaaggagg gaggcggccc gcaagg 46
<210> SEQ ID NO 52
<211> LENGTH: 46
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: RNA sequence displaying internal loop motif
<400> SEQUENCE: 52
gggagagggc cgccuccuuc cgaaaggaua aaggcggccc gcaagg 46
What is claimed is:
1. A method for identifying an RNA secondary structure
motif which interacts with a ligand, said method comprising:
providing a plurality of immobilized small molecule ligands
immobilized on a support at two or more different loadings,
wherein the two or more different loadings each comprise
distinct amounts of immobilized small molecule ligands in
the plurality of small molecule ligands, said two or more
different loadings being immobilized at separate, discrete
locations on the support, incubating the plurality of immo-
bilized small molecule ligands with two or more chase
oligonucleotides consisting of the sequence of SEQ ID NO:
4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO:7, SEQ ID
NO:8, SEQ ID NO:9, and SEQ ID NO:10, wherein the chase
oligonucleotides are designed to compete with invariant
regions of members of an RNA secondary structure motif
library for binding to the plurality of immobilized ligands
such that members of the RNA secondary structure motif
library bind to the immobilized small molecule ligands in
the plurality of immobilized small molecule ligands through
variant regions, wherein the members of the RNA secondary
structure motif library are selected from the group consisting
of an internal loop library, a hairpin loop library, a bulge
library, a multibranch loop library, a pseudoknot library, and
combinations thereof, contacting the plurality of immobi-
lized small molecule ligands with the RNA secondary struc-
ture motif library in the presence of the chase oligonucle-
otides under conditions effective for one or more members
of the RNA secondary structure motif library to bind with
one or more of the immobilized small molecule ligands, and
wherein the RNA secondary structure motif library com-
prises at least 4 members; and identifying members of the
RNA secondary structure motif library that are bound to
particular immobilized small molecule ligands in the plu-
rality of immobilized ligands, wherein said identifying the
members of the RNA secondary structure motif library that
are bound to each particular immobilized small molecule
30
ligand comprises: amplifying and determining the sequence
of the members of the RNA secondary structure motif
library that are bound at the discrete location on the support
corresponding to the particular immobilized small molecule
35 ligand; and using a dose-response curve and a dissociation
constant for each small molecule ligand loading to identify
members of the RNA secondary structure motif library
bound to lower small molecule ligand loading as having
greater amity for the small molecule ligand than members
40 of the RNA secondary structure motif library bound to
higher small molecule ligand loading, wherein the higher
small molecule ligand loading and lower small molecule
ligand loading comprise a serial dilution of the small mol-
ecule ligands, wherein the higher small molecule ligand
45 loading comprises up to 100 nanomoles of the small mol-
ecule ligand, and wherein the lower ligand loading com-
prises not less than one femtomole of the small molecule
ligand.
2. A method according to claim 1, wherein the support is
50 an agarose support.
3. A method according to claim 1, wherein at least 10
small molecule ligands are immobilized on the support.
4. A method according to claim 1, wherein the RNA
secondary structure motif library comprises at least 10
55 members.
5. A method according to claim 1, wherein the RNA
secondary structure motif library comprises at least 100
members.
6. A method according to claim 1, wherein at least 10
60 small molecule ligands are immobilized on the support and
wherein the RNA secondary structure motif library com-
prises at least 100 members.
7. A method according to claim 1, wherein said identify-
ing the members of the RNA secondary structure motif
65 library that are bound to a particular immobilized small
molecule ligand comprises: harvesting members of the RNA
secondary structure motif library that are bound at the
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discrete location on the support corresponding to the par-
ticular immobilized small molecule ligand; reverse tran-
scriptase polymerase chain reaction (RT-PCR) amplifying
the harvested members of the RNA secondary structure
motif library; cloning the RT-PCR amplified members of the s
RNA secondary structure motif library; and sequencing the
cloned RT-PCR amplified RNA members of the RNA sec-
ondary structure motif library.
